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INTRODUCTION 
Hepatitis  C  virus  is  an  important  cause  of  chronic  hepatitis  and  primary  
hepatocellular  carcinoma.  HCV  genotypes  can  vary  in  pathogenicity  and  can  
have  an  impact  on  treatment  outcome.  Acute  infection  becomes  persistent  
with  long  term  viremia  in  50-85%  of  infected  individuals.  Persistent  infection  
with  HCV  leads  to  cirrhosis  and  hepatocellular  carcinoma.  The  high  rate  of  
chronicity  and  lack  of  successful  vaccine  makes  Hepatitis  C  virus  a  serious  
threat  to  public  health.     
According  to  WHO,  Hepatitis  C  virus  is  an  emerging  infection  
affecting  an  estimated  130  -  150  million  people  worldwide  and  between  
3,50,000  and  5,00,000  of  them  die  each  year4.    Chronic  infection  with  
Hepatitis  C  virus  is  seen  in  3%  of  the  world’s  population  17.  Currently              
12.5  million  carriers  are  found  in  India.  HCV infection accounts  for  about  
15-20%  of  all  chronic  liver  diseases  and  among  5-10%  of  Hepatocellular  
carcinoma  cases.  It  is  the  most  common  cause  of  post  transfusion  hepatitis.    
Hepatitis  C  virus  infection  is  a  one  of  the  common  cause  of  liver  transplant  
worldwide. 
It  is  estimated  that  4-5  million  people  are  co-infected  with  HIV  and  
HCV4.  HCV  is  one  of  the  important  causes  for  mortality  in  HIV-  positive  
patients  on  HAART.  Most  people  infected  with  HCV  are  not  aware  that  
they  are  infected;  therefore  HCV  has  been  called  as  silent  epidemic.   
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When  serological  test  for  HBV  and  HAV  were  developed  during  
1970s  it  became  evident  that  the  majority  of  transfusion-related  hepatitis  
must  be  caused  by  yet  another  agent  called  NonA,  NonB.  Studies  in  
chimpanzees  confirmed  that  NANB  hepatitis  was  transmissible  and  due  to  a  
small  lipid  enveloped  virus.  It  was  first  identified  by  scientists  at  the  CDC  
and  NIH  in  1989.  It  was  detected  by  employing  molecular  techniques  on  
large  volumes  of  high  titer  infectious  chimpanzee  plasma7.  Key  contributors  
are  Harvey  Alter,  Daniel  Bradley  and  Michael  Houghton.  Following  its  
discovery,  screening  for  HCV  infection  has  led  to  a  decrease  of  risk  of  
transfusion-related  hepatitis  in  United  States.   
Hepatitis  C  virus  belongs  to  Flaviviridae  family,  genus  Hepacivirus  
(from  the  Greek  hepar,  hepatos  means  liver).  It  is  a  small,  single  stranded  
positive  sense  RNA  virus  with  icosahedral  symmetry.  The  length  of  genome  
is  approximately  9.6  kilo  bases.    It  is  50-60  nm  in  size  surrounded  by  an  
envelope  and  glycoprotein  spikes.  The  Hepatitis  virus  does  not  enter  the  
nucleus.  Viral  replication  takes  place  in  the  cytoplasm. 
HCV  genome  is  highly  mutative,  lacks  efficient  proof  reading  ability  
as  it  replicates.  Virions  undergo  evolution  with  time  and  circulate  in  infected  
individuals  as  a  population  of  diverse  but  closely  related  variants  referred  to  
as  “quasispecies”3.  Mutation  occurs  in  hyper  variable  region  of  the  genome  
coding  for  envelope  proteins  and  escapes  from  the  immune  system,  at  the  
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same  time  knocks  off  innate  immunity  resulting  in  chronic  persistent  
infection.   
The  virus  shows  considerable  genetic  diversity.  It  can  be  differentiated  
into  6  genotypes  and  nearly  100  subtypes  based  on  RNA  sequence  analysis.  
Genetic  variabilities  are  recognized  as  an  important  factor  for  the  prognosis,  
monitoring  and  outcome  of  HCV  mediated  chronic  liver  disease.  HCV  
genotypes  have  distinct  geographical  distribution.  Genotype  1  is  common  
accounting  for  60%  global  infection.  Type  3  is  prevalent  in  South  East  Asia.  
Most  of  the  studies  in  India  reported  the  prevalence  of  genotype  3  in  North  
and  genotype  1  in  South. 
HCV  genotypes  differ  from  each  other  by  30-35%  nucleotide  sites.  
Strains  from  each  subtype  vary  at  <15%  of  nucleotide  sites.    Duration  of  
treatment,  cure  rates,  the  need  for  interferon,  ribavarin  and  recently  a  
combination  therapy  with  the  new  Direct  Acting  Antivirals  (DAA)  also  base  
on  the  genotypes  and  subtypes.    The  formulation  of  treatment  strategies  
using  Direct  Acting  Antiviral  requires  knowledge  of  prevalence  of  HCV  
genotype.  HCV  genotype  1,4,5,6  has  been  reported  to  show  poorer  response  
to  conventional  antiviral  drugs.  While  up  to  80%  of  the  genotypes  2  and  3  
can  be  cured  with  the  standard  treatment.  HCV  1b  is  implicated  in  accelerated  
progression  of  chronic  liver  disease.   
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The  incubation  period  of  Hepatitis  C  virus  averages  6-8weeks.     
Hepatitis  C  virus  can  cause  acute  or  chronic  infection.  Acute  infections  are  
usually  asymptomatic  or  clinically  mild.  The  infection  is  usually  recognized  
only  when  it  becomes  chronic.  Spontaneous  clearance  of  infection  is  unusual  
in  acute  Hepatitis  C,  with  nearly  50-90%  of  the  infection  becoming  chronic.    
Neutralising  antibodies  are  produced  during  course  of  infection,  yet  the  virus  
mutates  to  escape  from  immune  system.  This  leads  to  persistent  infection.  
Cirrhosis  is  a  significant  complication  of  chronic  infection.  Hepatitis  C  
infection  is  an  independent  risk  factor  for  HCC  after  development  of  cirrhosis.   
Extrahepatic  immunological  manifestations,  such  as  cryoglobulinemia,  
autoimmune  thyroiditis,  membranoproliferative  glomerulonephritis  and  
Rheumatoid  factors  are  a  prominent  part  of  hepatitis  C  infection.  Major  
causes  for  death  in  patients  with  HCV-related  cirrhosis  are  portal  hypertension  
and  hepatocellular  carcinoma3. 
Blood  transfusion,  Intravenous  drug  abuse,  unsafe  therapeutic  injections  
and  health  care  related  procedures  are  common  modes  of  spread  of  Hepatitis  
C  virus;  Less  common  routes  being  vertical  and  sexual  transmission.  Major  
route  of  Hepatitis  C  infection  is  IV  drug  abuse  in  developed  countries.  
Common  routes  of  HCV  transmission  in  India  are  blood  transfusion  and  
unsafe  therapeutic  procedures.  This  is  shown  by  several  studies  where  the  
antibody  positivity  rate  for  patients  who  transfused  blood  before  1995  was  
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16%  and  patients  who  received  blood  transfusion  after  1995  was  6%47.  In  
intravenous  drug  abuse  antibody  prevalence  ranges  from  5-93%  whereas  in  
hemodialysis  patients  it  ranges  from  4.3%-45.2%.     
The  first  step  used  for  the  detection  of  Hepatitis  C  virus  is  serological  
tests.  ELISA  and  the  recombinant  immunoblot  assay  are  in  their  third  
generations  with  increased  sensitivity  and  more  specificity.  Serological  false  
negativity  in  HCV  may  occur  in  immuno-compromised  individual  and  during  
acute  phase  of  infection  i.e  preseroconversion  window  period.  False  positive  
results  can  also  occur  frequently.  One  possible  reason  is  people  who  clear  
infection  may  remain  anti-HCV  positive  for  many  years.  Serological  tests  for  
Hepatitis  C  Virus  cannot  differentiate  people  who  had  spontaneous  resolution  
from  those  who  are  chronically  infected.    It  is  necessary  to  determine  
presence  of  virus  in  the  circulation.   
The  molecular  diagnostic  techniques  are  the  most  sensitive  and  specific  
tests.  Molecular  technique  detects  HCV  RNA  and  also  confirms  acute  stage  
of  infection.  Quantitative  assay  is  necessary  for  monitoring  prognosis.  The  
analysis  of  Hepatitis  C  Virus  genotypes  has  become  an  important  factor  for  
planning  treatment.   
There  is  a  paucity  of  data  available  about  the  prevalence  of  various  
HCV  genotypes  in  patients  with  chronic  liver  disease  in  Coimbatore.  
Considering  the  importance  of  Hepatitis  C  virus  infection  among  chronic  
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liver  disease  patients  and  its  associated  morbidity  and  mortality,  this  study  
has  been  undertaken  in  CMCH,  a  tertiary  care  hospital.   
The  study  deals  with  sero-prevalence  and  predominant  genotypes  
present  among  chronic  liver  disease  patients  attending  medical  
gastroenterology  and  allied  departments. 
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AIMS  AND  OBJECTIVES 
 
AIM: 
To  study  the  prevalence,  risk  factors  of  hepatitis  C  virus  infection  in  
chronic  liver  disease  patients  attending  various  clinical  departments  at  
CMCH  and  analyse  whether  specific  genotype  is  associated  with  an  
increased  risk  of  cirrhosis  and  Hepatocellular  carcinoma 
 
OBJECTIVES: 
 
1. To  screen  hepatitis  C  virus  infection  in  patients  with  chronic  liver  
disease  by  ELISA  method. 
2. To  detect  HCV  RNA  by  real  time  RT-PCR. 
3. To  confirm  the  Hepatitis  C  virus  sero-positivity    by  RT-  PCR. 
4. To  identify  the  genotypes  by  RT-PCR .  
5. To  evaluate association  of  genotypes  in  patient  with  chronic  liver  
disease. 
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REVIEW  OF   LITERATURE 
Hepatitis  Viruses 
Many  viruses  can  produce  damage  to  the  liver,  most  common  being  
primary  hepatitis  viruses.  Yellow  fever,  Herpes  simplex  virus,  Rubella,  
Enterovirus  and  Adenoviruses  can  also  cause  hepatitis1.  Ebstein  Barr  virus  
and  cytomegalovirus  can  cause  symptomatic  hepatitis.  The  primary  hepatitis  
viruses  are   diverse  group.  The  alphabet  soup  of  hepatitis  is  summarized  
below. 
Hepatitis  A  virus 
Infectious  hepatitis  is  caused  by  Hepatitis  A  Virus.  It  belongs  to  genus  
Hepatovirus  in  the  family  Picornaviridae.  HAV  is  transmitted  principally  by  
faeco-oral  route. 
Hepatitis  B  virus 
HBV  is  the  most  common  type  among  hepatitis  viruses.  It  belongs  to  
the  family  Hepadnaviridae  under  the  genus  Orthohepadnavirus.  It  causes  
serum  hepatitis.  Infection  with  HBV  can  also  lead  to  chronic  hepatitis.  
Hepatic  complications  are  cirrhosis  and  hepatocellular  carcinoma. 
Hepatitis  D  virus 
It  is  a  defective  virus  which  cannot  replicate  by  itself  and  requires  
Hepatitis  B  virus  for  its  survival. 
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Hepatitis  E  virus 
It  causes  enterically  transmitted  hepatitis  primarily  occurring  in  young  
adult.  It  has  been  assigned  to  a  unique  genus  Hepevirus  under  the  family  
Hepeviridae. 
Hepatitis  G  virus 
HGV  was  discovered  in  1995.  It  is  related  to  family  Flaviviridae,  
under  the  genus  Pegivirus.  It  is  transmitted  through  contaminated  blood  or  
blood  products,  or  via  sexual  contact.  It  is  not  hepatotropic  and  does  not  
cause  hepatitis. 
Hepatitis  virus  infection 
Pathology 
The  word  ‘Hepatitis’  means  inflammation  of  the  liver.  The  
parenchymal  changes  are  spotty  degeneration  with  necrosis,  a  diffuse  lobular  
inflammatory  reaction,  and  disruption  of  liver  cell  cords  which  are  
accompanied  by  reticuloendothelial  cell  hyperplasia,  periportal  infiltration  by  
mononuclear  cells  and  cell  degeneration.  Localised  areas  of  necrosis  and  
accumulation  of  macrophages  near  degenerating  hepatocytes  are  observed. 
Histological  features  of  Chronic  active  hepatitis  are  inflammation,  
necrosis  and  collapse  of  the  normal  reticulum  framework  with  bridging  
between  the  portal  triads  or  terminal  hepatic  veins1. 
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Hepatitis  C  Virus 
Ever  since  its  discovery  in  1989  as  a  causative  agent  of  transfusion  
associated  non-A  non-  B  hepatitis7,  HCV  has  been  increasingly  recognised  
as  a  global  health  problem.  It  is  a  predominant  cause  of  transfusion  associated  
hepatitis  and  chronic  liver  disease  worldwide,  more  so  in  the  developing  
countries.  Chronic  HCV  is  associated  with  wide  range  of  disease  ranging  
from  liver  cirrhosis  end  stage  liver  disease  and  HCC. 
Epidemiology 
Global  burden 
HCV  has  worldwide  distribution,  affecting  persons  of  all  ages,  races,  
gender  and  regions  of  the  world.  HCV  accounts  for  more  than  350,000  
deaths  annually4,  mortality  in  HCV  infection  is  attributed  to  liver  cirrhosis  
and  hepatocellular  carcinoma2.  Prevalence  higher  than  the  global  average  has  
been  reported  from  Africa  (3.2%)  and  the  Middle  East  (4.7%)  3.                              
The  Scandinavian  countries  have  prevalence  of  0.5%  where  as  in  Egypt  it  
is  >20%17. 
Indian  scenario 
HCV  infection  is  an  emerging  cause  of  liver  disease  in  India.  Blood  
transfusion  and  unsafe  injection  practices  are  believed  to  be  two  major  routes  
of  transmission  of  HCV  in  India  where  about  20  million  people  are  known  
to  have  been  affected  by  HCV. 
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The  largest  study  by  Chowdhury  and  colleagues  from  west  Bengal  
showed  the  prevalence  of  HCV  antibody  in  general  population  is  about  
0.87%6  and  among  blood  donor  population  1.8-2.5%17.  81%  of  those  who  
were  anti-HCV  positive  showed  the  presence  of  HCV  RNA. 
Scenario  in  Tamilnadu 
A  study  by  V.  Gowri  et  al  from  Vellore  showed  overall  sero-
prevalence  in  the  various  group  was  0.22%11.  The  sero-prevalence  of  HCV  
is  8.2%  in  liver  disease  patients16. 
Hepatitis  C  Virus 
Classification  and  taxonomy: 
HCV  has  been  classified  as  a  member  of  the  family  Flaviviridae,  
along  with  other  related  positive  stranded  RNA  viruses.  The  virus  however,  
is  distinct  enough  to  merit  classification  within  a  separate  genus,  Hepacivirus.  
Closely  related  genus  include  the  genus  the  Flavivirus  eg.,  yellow  fever  virus  
and  dengue  viruses  and  the  genus  pestivirus  eg.,  bovine  viral  diarrhea.   
Structure  of  the  virus 
It  is  a  spherical  enveloped  virus  approximately  55nm  in  diameter.  
HCV  genome  is  9.6  kilo  bases  long3.  It  is  a  positive  sense  single  standard  
RNA  virus.  Its  genome  has  one  large  open  reading  frame  which  accounts  
for  over  95%  of  the  sequence.  It  encodes  for  a  single  large  polyprotein,  
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which  is  about  3010  amino  acids  long  and  it  undergoes  post  transitional  
modifications  to  yield  10  viral  proteins.  Flanking  the  ORF  at  both  5’  and3’  
ends  are  highly  conserved  untranslated  regions  (UTR),  which  mediate  crucial  
steps  in  viral  translation  and  replication1. 
Untranslated  regions 
The  HCV  5’UTR  is  341  nucleotides  long  and  contains  two  overlapping  
functional  regions.  The  5’  125  nucleotides  are  needed  for  viral  replication  
whereas  the  remainder  of  the  5’  UTR  appear  to  play  an  accessory  role  in  
this  process.  It  has  an  overlapping  approximately  300  nucleotide  long  
segment,  known  as  “internal  ribosomal  entry  site”  (IRES)  which  directs  the  
cap  independent  translation  of  the  viral  ORF3. 
The  3’  UTR  consists  of  30-60  nucleotide  segment  and  highly  variable  
poly-U/UC  tract  of  50-100  nucleotides.  There  is  a  highly  conserved  98  -  
base  sequence  in  the  downstream  of  the  poly  U/UC  Tract  designated  as  
3’X”  region.  This  highly  structured  3’  terminal  98  base  sequence  is  the  most  
conserved  region  of  HCV  genome.  The  kissing  loop  interaction  between  3’X  
region  with  the  NS5B  coding  region  and  33  consecutive  U  residues  segment  
in  the  poly  U/UC  tract  is  essential  for  viral  RNA  replication.   
Recent  work  shows  that  the  poly  U/UC  tract  is  the  principle  pathogen  
associated  molecular  pattern  sensed  by  human  cytoplasmic  pattern  recognition  
receptor.  The  unusual  feature  of  HCV  replication  that  involves  the  UTRs  is  
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the  presence  of  complimentary  sequences  for  liver  specific  microRNA  
122(miR122).  This  interaction  is  found  to  be  necessary  for  HCV  replication,  
potentially  contributing  to  the  hepatotropism    of    HCV3. 
Polyprotein 
It  is  encoded  by  open  reading  frame  and  it  is  co-translationally  
processed  into  atleast  10  proteins.  It  includes  three  “structural”  proteins:  the  
nucleocapsid  protein,  core(C)  and  two  envelope  proteins  (E1  and  E2);  two  
proteins  that  are  essential  for  virion  production  but  are  not  required  for  viral  
RNA  replication  (p7  and  NS2)  and  five  non-structural  proteins  (NS3,  NS4A,  
NS4B,  NS5A,  NS5B)  which  form  viral  RNA  replicase  complex.   
 
Structural  proteins 
The  structural  component  of  the  virus  particle  is  formed  by  a  
multifunctional  core  protein.  It  is  highly  basic  in  nature.  The  core  protein  is  
known  to  interfere  with  anti-  HCV  immune  responses  through  a  variety  of  
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mechanisms  including  NK  cell  inhibition  via  upregulation  of  MHC  class  1  
expression,  inhibition  of  T  cell  proliferation  via  interaction  with  complement  
receptor  and  interaction  with  the  cytoplasmic  tail  of  several  cellular  receptors  
belonging  to  the  TNF  receptor  family.   
The  core  protein  is  immunogenic,  both  core  protein  and  its  antibody  
are  typically  present  in  the  serum  of  infected  individuals.   
HCV  has  two  major  envelope  proteins  (E1  andE2)  which  are  produced  
from  HCV  polyprotein.  The  E1and  E2  protein  are  glycosylated  with  sugar  
moieties  HCV particles assemble and exit the cell by budding into 
intracytoplasmic  vesicles  and  then  follow  the  secretary  pathway  for  release3. 
A  hypervariable  segment  approximately  30  amino  acid  residues  in  
length  near  the  amino  terminus  of  E2  is  called  as  HVR  1.  It  is  the  most  
genetically  variable  segment  of  the  envelope  protein.  It  is  assumed  to  exist  
as  a  polypeptide  long  on  the  surface  of  the  virion.  HVR-1  harbours  one  or  
more  neutralization  epitopes  and  that  is  a  site  of  mutations  causing  immune  
escape  during  acute  and  chronic  infection3. 
P7  and  NS2  proteins 
These  two  proteins  may  play  a  role  in  viral  particle  assembly  or  
egress  from  the  cell.  The  protein  is  produced  by  cleavage  of  E2  near  its  
carboxyl  terminus.  This  is  a  small  63aa  hydrophobic  polypeptide  which  
appears  to  be  capable  of  forming  a  voltage  gated  ion  channel.  Its  activity  
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is  required  for  the  production  of  infectious  virions,  inhibited  in  vitro  by  
amantadine  and  long  alkyl  chain  imino-sugar  derivatives,  representing  a  
possible  therapeutic  target3. 
The  NS2  protein  is  a  membrane  associated  dimeric  cysteine  protease  
with  two  composite  active  sites  which  mediate  cleavage  at  the  NS2/NS3.  
The  transmembrane  and  protease  domain  structures  of  NS2  are  needed  for  
the  formation  of  infectious  particles    in  cell  culture  whereas  the  protease  
activity  is  not.   
Non-structural  proteins 
These  proteins  are  required  for  RNA  replication  which  occurs  in  a  
membrane  associated  replicase  complex  within  the  cytoplasm.  The  NS3  
protein  possesses  serine  protease  activity  in  its  amino  terminal  end  and  an  
RNA  helicase  with  NTPase  activity  in  its  carboxy  terminus.  Its  activity  
depends  upon  zinc.  It  is  responsible  for  the  NS3/NS4A  cis  cleavage  and  
cleavages  of  NS4A/NS4B,  NS$B/NS5A,  NS5A/NS5B.  TheNS4  protein  acts  
as  cofactor  for  the  NS3  protease.  An  amino  terminal  segments  of  the  protein  
binds  the  NS3/NS$A  complex  to  intracellular  membrane,  while  NS4A  
complex  also  interacts  with  NS5A. 
NS4B  is  a  hydrophobic  membrane  associated  protein,  which  mediates  
modifications  of  the  ER  membrane  that  occur  in  association  with  replicase  
assembly  and  also  inhibits  normal  ER-to-  Golgi  secretory  pathways. 
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NS5A  is  a  membrane  bound  anchored  RNA  binding  phosphoprotein  that  
appears  to  play  role  in  RNA  replication.  NS5B  is  a  membrane  bound  protein  
that  contains  a  Gly-Asp-Asp  motif  characteristic  of  RNA  dependent  RNA  
polymerase  and  is  considered  as  the  catalytic  core  of  the  replicase  complex.  
As  with  a  enzymatic  activity  of  NS3  protein,  the  NS5B  RNA  polymerase  
has  proven  as  a  useful  target  for  drug  development  with  nucleotide  analogue  
and  non-nucleotide  small  molecule  inhibitor  as  well  as  cyclosporine  A  
analogue. 
Replication 
Life  cycle  of  HCV  begins  with  attachment  and  internalisation  of  virus  
into  the  host  cell.  It  is  mediated  by  viral  envelope  glycoproteins  E1  and  E2.  
A  number  of  host  cellular  receptor  such  as  CD81,  LDL  receptor,  and  human  
scavenger  receptor  SR-B1,  DC-  SIGN,  claudin-1  and  occludin  are  believed  
to  be  necessary  for  this  process.   
After  attachment  and  entry,  uncoating  of  the  nucleocapsid  occurs,  
which  leads  to  release  of  the  viral  RNA  into  host  cytoplasm.  As  it  is  a  
positive  stranded  RNA  it  act  as  messenger  RNA  and  translation  of  the  
polyprotein  is  initiated  following  ribosomal  mediated  binding  mediated  by  
the  IRES  domain.   
This  is  followed  by  a  number  of  cleavages  of  the  polyprotein  by  both  
cellular  and  viral  proteases  which  results  in  the  formation  of  various  structural  
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and  non-structural  proteins.  After  cleavage  the  core  protein  stays  in  cytoplasm  
while  E1  and  E2  are  secreted  in  to  the  endoplasmic  reticulum.  The  non-
structural  proteins  assemble  to  form  a  membrane  bound  replication  complex. 
The  viral  NS5B  RNA  dependent  RNA  polymerase  (RdRp)  facilitates  
the  synthesis  of  a  negative  stranded  intermediate.  This  consequently  serves  
as  a  template  for  synthesis  of  positive  stranded  RNA.    This  RNA,  core  
protein,  E1  and  E2  proteins  gets  packaged  into  new  viral  particles.  After  
maturation  and  assembly,  newly  produced  virions  are  released  from  the  host  
cell  through  the  secretary  pathway. 
Genetic  diversity 
Quasispecies  variation 
The  high  turnover  of  virion  in  the  absence  of  proofreading  ability  by  
NS5B  RNA  polymerase  and  tolerance  of  many  genomic  regions  for  multiple  
nucleotides  resulting  in  the  rapid  accumulation  of  viral  mutations.  
Accumulation  of  a  multitude  of  closely  related  but  distinct  HCV  variants  
within  an  infected  individual  are  known  as  quasispecies.   
Viral  RNAs  containing  spontaneous  mutation  within  the  HVR  - 1  
segment  of  the  E2  protein  may  be  favoured  for  survival  in  the  host  when  
they  reduce  the  binding  of  pre-existing  neutralising  antibodies  to  the  envelope.  
Quasispecies  variation  occurs  in  a  single  individual3.    This  heterogeneity  of  
the  viral  population  may  rapidly  select  treatment  resistant  clones,  thus  
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possibly  reducing  treatment  efficiency  of  the  new  direct  acting  antiviral  drugs  
recently  approved  for  treating  HCV  infection. 
HCV  Genotypes 
Tremendous  genetic  heterogeneity  and  variation  among  sequences  of  
HCV  isolated  from  different  individuals  that  has  led  to  their  classification  
into  genotypes  and  subtypes.  Genotyping  and  subtyping  of  HCV  is  useful  
for  understanding  of  epidemiology,  vaccine  development,  clinical  management  
and  therapeutic  measures  against  chronic  HCV  infection.   
Genotyping  is  done  by  sequencing  either  the  5’UTR/core,  NS3  or  of  
the  NS5b  region  of  HCV  genome.  Phylogenetic  evaluation  of  HCV  sequences  
recovered  from  different  geographic  zones  suggests  that  there  are  6  genotypes  
or  clades.  Diversity  of  the  genotypes  at  the  nucleotide  level  is  estimated  to  
be  about  30%.     
Within  individual  HCV  genotypes  strains  can  be  further  grouped  into  
subtypes  that  generally  share  75%-85%  nucleotide  identity  within  the  core  
E1  and  NS5B  regions  of  genome.  Alteration  in  the  rate  of  HCV  
multiplication,  response  to  interferon  therapy,  or  pathogenicity  of  the  virus  
due  to  differential  activity  of  HCV  proteins  is  because  of  the  difference  in  
nucleotide  sequence. 
The  quasispecies  variations  that  exist  within  a  single  person  generally  
have  91-99%  identity  in  these  regions3.  This  genetic  diversity  is  independent  
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of  differences  in  clinical  disease  although  variations  exist  in  response  to  
antiviral  therapy  according  to  viral  genotypes1. 
Recently,  studies  emphasised  clinical  importance  of  typing  and  
subtyping.  Genotype  1  in  particular  responds  poorly  to  IFN-alpha,  while  
genotypes  2,  3  can  be  treated  favourably.  Studies  on  Japanese  patients  
showed  that  the  outcome  of  HCV  subtype  1b  infection  treated  with  alpha  
interferon  therapy  is  correlated  with  genetic  diversity  in  the  NS5A  gene.  
Infection  with  genotype  1  may  progress  rapidly  to  cirrhosis  and  HCC  
compared  to  genotype  2  and  3. 
Viral  tropism 
HCV  multiplies  inside  the  liver  cells,  and  the  liver  specific  expression  
of  miR122  may  contribute  to  this  specificity.  Some  studies  observed  the  
presence  of  negative  strand  HCV  RNA  in  T  cells,  B  cells  and  monocytes  
especially  in  patients  affected  by  CHC. 
Global  distribution  of  HCV  genotypes 
Genotype  1  found  to  be  the  commonest  genotype  with  a  worldwide  
distribution  in  USA  and  northern  Europe29.  Genotypes  2  and  3  are  also  
found  worldwide,  with  a  higher  prevalence  in  Europe,  North  America  and  
Japan30.  Genotype  3  infection  is  common  in  Southeast  Asia  and  in  the  Indian  
subcontinent  and  is  also  prevalent  in  intravenous  drug  users  in  the  USA  &  
Europe.  Genotype  4  infections  are  mainly  present  in  Northern  Africa  and  
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Middle  Eastern  Countries.  Genotype  5  appears  to  be  restricted  to  South  
Africa.  Genotype  6  is  restricted  to  intravenous  drug  users  in  Southeast  Asia  
and  more  recently  in  Australia30,  31,  32. 
Distribution  of  HCV  genotypes  in  India 
There  are  a  few  studies  which  have  attempted  to  establish  the  
distribution  of  HCV  genotypes  in  the  country.   
In  the  largest  such  study  by  Christdas  et  al.12,  spanning  over  a  decade  
2002-2012  and  including  451  patients  from  various  parts  of  the  Indian  
subcontinent,  genotype  3  was  found  to  be  the  most  predominant  63.85%  
followed  by  genotype  1,4,6  (25.72%,  7.5%  and  2.7%  ).  Genotype  2  was  
found  in  only  one  patient  from  Northeast  India  and  genotype  5  not  detected  
till  now.   
Genotype  1  was  commoner  in  South  India  while  genotype  3  was  more  
prevalent  in  East  and  North-east  parts  of  the  country.  Genotypes  4  and  6  
appeared  to  be  restricted  geographically  to  the  southern  and  north  eastern  
parts  of  the  country  respectively,  which  has  been  published  previously  as  
well33,  34.  Recombinant  strains  of  genotype  1  and  2  were  isolated  from  two  
patients. 
In  another  study  on  398  patients  from  North  and  Central  India  by  
Hissar  et  al,  the  findings  were  similar.  Genotype  3  was  the  commonest  
genotype,  seen  in  80.2%  patients,  followed  by  genotype  1  in  13.1%  patients35.  
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Genotypes  4(3%)  and  2(2.5%)  were  rare.  There  were  no  cases  of  genotypes  
5  and  6  infections.  Five  patients  showed  mixed  genotype  infection.   
The  study  by  Sompal  singh  et  al  on  chronic  hepatitis  C  cases  in  north  
India  showed  that  Genotype  3  was  found  to  be  the  widespread  genotype  25.   
Natural  History  and  Pathogenesis 
HCV  RNA  can  be  detected  in  plasma  within  days  of  exposure,  often  
1-4weeks  before  liver  enzyme  levels  rises.  Viremia  reaches  maximum  in  the  
first  8  to  12wks  of  infection  then  falls  to  lower  levels  and  persists.  In  some  
instances  plasma  RNA  becomes  undetectable  in  the  first  few  months  and  
remains  undetectable  indefinitely  (viral  clearance). 
In  other  instances,  Viremia  is  inconsistently  detected  early  and  a  stable  
pattern  of  recovery  or  persistence  is  not  evident  for  more  than  6  month.  In  
some  cases  intermittent  Viremia  may  reflect  reinfection  which  has  been  
observed  in  active  intravenous  users.  In  other  cases  rebounding  Viremia  may  
indicate  escape  from  an  initially  successful  viral  response.     
Overall  viremia  persists  in  50-85%  of  acutely  infected  persons.  HCV  
infection  more  often  persists  in  African,  American  people  than  whites  and  
in  person  infected  with  HIV  than  immunocompetent  persons.  Persons  who  
develop  clinical  symptoms  are  more  likely  to  clear  infection.  This  correlates  
with  the  more  vigorous  immune  response  in  them.  Noththless  it  is  difficult  
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to  define  the  immunological  mechanisms  of  HCV  persistence  and  their  
genetic  determinants. 
   
 
Acute  hepatitis  c  and  spontaneous  clearance 
Acute  hepatitis  can  be  caused  by  HCV.  Acute  infection  with  HCV  is  
mostly  asymptomatic.  It  is  possible  to  detect  HCV  RNA  in  most  of  the  
patients  within  1  to  2  weeks  &  is  followed  by  an  increase  in  liver  enzymes  
by  2-8 weeks.  Symptoms  of  acute  hepatitis  develop  within  3  to  12  weeks  of  
exposure  to  the  virus,  in  about  25  to  30%  of  patients.  However  anti-HCV  
is  not  reliable  in  the  diagnosis  of  acute  infection  as  up  to  about  thirty  
percent  of  cases  will  test  negative  at  the  onset  of  symptoms  because  of  
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delayed  sero-conversion.  Almost  all  patients  will  eventually  develop  anti  
HCV  whereas  the  titre  will  be  low  in  the  context  of  immunosuppression9. 
Chronic  HCV  infection  and  progression  of  fibrosis 
Persistence  of  HCV  RNA  for  more  than  6  months  after  onset  of  
infection  defines  chronic  hepatitis  C.  Age  at  acquisition  of  infection,  sex,  
race,  immune  status  of  the  patient,  co-infection,  along  with  other  host  and  
viral  factors  influence  chronicity  of  the  infection8.  The  early  phase  of  the  
infection  is  marked  by  appearance  of  HCV  RNA,  followed  by  rise  in  serum  
transaminases. 
It  must  be  noted  that  in  the  time  period  of  evolution  from  acute  
hepatitis  to  chronic  hepatitis,  HCV  RNA  and  enzyme  levels  can  vary  
remarkably.  Once  the  infection  gets  persistent,  viral  load  tends  to  stabilise.  
Spontaneous  resolution  of  chronic  infection  is  unusual.  Histological  finding  
is  the  main  criterion  for  assessing  severity  and  disease  progression26. 
Fatigue,  abdominal  discomfort,  nausea,  and  poor  appetite  are  the  most  
common  symptoms  seen9.  The  disease  may  remain  clinically  silent  for  
decades.  However,  hepatocellular  inflammation  and  fibrosis  continues,  leading  
to  progressive  liver  disease.  The  rate  of  progression  of  the  disease  is  again  
determined  by  a  multitude  of  modifiable  and  non-modifiable  factors.   
Progressive  hepatic  fibrosis  may  lead  to  cirrhosis  and  decompensated  
liver  disease.  Such  cases  have  a  high  risk  of  developing  hepatocellular  
24 
 
carcinoma,  with  1  to  4%  of  patients  developing  this  complication  each  year10.  
It  usually  takes  more  than  two  decades  of  infection  for  these  long  term  
complication  to  develop,  unless  accelerated  by  coexistent  factors.  Prognosis  
of  patients  with  cirrhosis  is  influenced  by  the  onset  of  complications  that  
occur  at  a  yearly  rate  of  about  5-7%  patients. 
Extrahepatic  manifestations   
Seventy  four  percent  of  patients  have  reported  Extrahepatic  
manifestations.  Extrahepatic  manifestations  are  Cryoglobulinemia,  
Membranoproliferative  glomerulonephritis,  Raynaud  syndrome,  Sjögren  
syndrome,  Necrotizing  cutaneous  vasculitis,  Non-Hodgkin  lymphoma. 
Patrice  Cacoub  et  al  study  showed  that  Mixed  cryoglobulin,  RF  
activity,  and  Antinuclear  antibody,  Anticardiolipin  antibody,  Anti-thyroid  
antibody  and  Anti-smooth  muscle  antibodies  are  most  frequently  seen  
immunological  abnormality  in  HCV27.   
A  minimum  of  one  immunologic  abnormality  can  be  seen  in  up  to  
fifty  three  percent  of  HCV  patients.  Signs  and  symptoms  of  a  connective  
tissue  disease  (except  for  mixed  cryoglobulinaemia)  are  not  caused  by  these  
autoantibodies.    Autoantibody  synthesis  in  these  cases  is  due  to  the  HCV-
induced  over  activation  and  proliferation  of  B  lymphocytes. 
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Mixed  cryoglobulinaemia 
HCV  infection  is  the  cause  of  Mixed  Cryoglobulinaemia  in  roughly  
about  eighty  percent  of  the  patients.   
Sjögren  syndrome 
HCV  infection  has  long  been  suspected  as  a  potential  cause  of  SS.  
There  is  a  possible  relation  between  hepatitis  C  virus  and  Sjogren  syndrome  
as  it  can  be  excreted  in  saliva.   
Disease  progression 
The  major  pathological  outcome  of  chronic  HCV  infection  is  
development  of  hepatic  fibrosis.  It  usually  followed  by  progression  to  
cirrhosis  and  then  to  hepatocellular  carcinoma.  This  complication  usually  
takes  more  than  twenty  years  after  the  onset  of  infection.  It  has  been  
estimated  that  probability  of  cirrhosis  occurring  within  twenty  yrs.  of  infection  
is  5%-25%3.  HCV  infection  is  usually  asymptomatic.  It  is  difficult  to  assess  
rate  of  progression  of  fibrosis  prior  to  clinical  manifestion. 
Studies  showed  that  mortality  was  slightly  more  in  patients  with  post  
transfusion  hepatitis  (3%)  than  control  group  (1.5%)  3.     
The  leading  environmental  determinant  appears  to  be  alcohol  ingestion.  
Excessive  alcohol  consumption  and  HCV  infection  independently  can  cause  
cirrhosis;  Exposure  to  both  will  have  synergistic  effect.  Alcohol  and  HCV  
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infection  may  cause  microvesicular  steatosis,  suggesting  a  common  pathway  
involving  mitochondrial  injury. 
Co-infection  with  HBV  can  also  accelerate  disease  progression.  High  
level  of  HCV  viremia  is  found  in  HIV  which  can  lead  to  accelerated  
progression  of  liver  disease.  Schistosomiasis  co  infection  is  associated  with  
much  more  rapid  progression  of  HCV  mediated  fibrosis  in  Egypt90.    
Accelerated  progression  of  liver  disease  is  also  expected  in  
immunosuppression  associated  with  agammoglobulinemia  and  organ  
transplant. 
Immune  response  to  HCV  Infection 
HCV  infection  triggers  sequence  of  intracellular  events  that  lead  to  
the  development  of  an  antiviral  state  in  the  infected  cell  and  the  surrounding  
tissue.  Following  viral  entry  into  the  host,  pathogen  associated  molecular  
patterns  in  the  viral  genome  are  recognised  by  PAMP  receptors  expressed  
on  the  host  cell,  initiating  the  host  immune  response.  Retinoic  acid  inducible  
gene  1(RIG-I)  and  Toll-like  receptor  3  are  two  major  receptor  pathways  
triggered  by  HCV  RNA.  This  subsequently  stimulates  interferon  stimulated  
genes  inducing  endogenous  interferon  production,  and  thus  building  the  initial  
antiviral  defence36.  For  strategies  to  evade  host  immune  response,  it  is  the  
balance  between  the  two  which  determines  progression  of  the  disease.     
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Innate  Immune  response 
Interferons  and  Interferons  stimulated  genes 
The  first  response  to  HCV  infection  is  by  the  production  of  
endogenous  Interferons  by  the  infected  liver  cells.  This  begins  With  Toll  
like  receptor  -3  and  RIG-  1  mediated  sensing  of  HCV  RNA,  which  through  
various  mediators  leads  to  signalling  of  IFN  regulatory  factor  3.  This  induces  
the  transcription  of  IFN-  
uninfected  neighbouring  cells  via  paracrine  effects,  limiting  cell  to  cell  spread.  
Interferon-beta  binds  to  IFN-
This  causes  stimulation  of  Interferon  stimulated  genes,  which  have  different  
antiviral  properties,  such  as  degradation  of  viral  nucelic  acid,  inhibition  of  
translation  and  destabilisation  of  secondary  structures  of  viral  RNA.   
Some  pattern  recognition  and  signalling  molecules  like  RIG-1  are  also  
ISGs,  whose  levels  markedly  increase  from  low  basal  level,  increasing  the  
sensitivity  of  downstream  signalling  in  infected  tissues  and  promoting  IFN  
diversifying  the  IFN  response  and  providing  a  positive  feedback  to  ISG  
expression36,  37
component  of  immune  response. 
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Adaptive  immune  response 
Humoral  immunity 
Within  months  of  infection,  antibodies  are  detectable  in  blood  to  
multiple  recombinant  antigens  that  correspond  to  structural  and  non-structural  
protein  genes.  These  antibodies  are  neutralising  in  nature,  differing  in  their  
mechanism  of  neutralising.  The  antibodies  are  isolate  specific  and  together  
with  CD8  cells  contribute  to  the  evolution  of  HCV  quasispecies  by  exerting  
selection  pressure.  Lack  of  temporal  relation  of  these  antibodies  to  viral  
recovery  and  demonstration  of  HCV  clearance  in  individual  with  
agammoglobulinemia  led  to  the  belief  that  humoral  immune  response  was  
neither  necessary  nor  sufficient  for  viral  clearance37,  38.   
However  recent  studies  showed  the  role  of  the  neutralising  antibodies  
in  outcome  of  the  disease.  Early  and  rapid  production  of  antibodies  may  
lead  to  spontaneous  resolution  of  infection.  In  case  of  chronic  infection  
where  antibodies  are  either  absent  or  very  low  in  titre  in  early  phase  of  the  
infection  influencing  the  outcome  of  the  disease49.   
Cellular  immunity 
HCV  specific  CD8  and  CD4  T  cell  responses  were  known  for  being  
critical  for  HCV  clearance.  Functional  CD4  response  is  an  essential  factor  
which  decides  the  fate  of  Hepatitis  C  Virus  infection  by  production  of  
Interleukin-2  and  Interferon-            
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CD4  cells  is  seen  in  individuals  who  clear  the  virus  and  impaired  or  weak  
response  is  seen  in  those  who  progress  to  chronic  disease39. 
 On  the  other  hand  HCV  specific  CD8  cells  are  detectable  in  cases  of  
acute  infection  irrespective  of  virological  outcome.  In  acute  infection  some  
CD8  cells  show  a  “stunned”  phenotype  and  are  unable  to  produce  IFN-
However,  as  CD4  T  cell  responses  develop  and  viraemia  declines,  this  
dysfunction  resolves  and  memory  cells  become  detectable40. 
 In  cases  of  recovery,  durable  populations  of  memory  T  cells  are  seen.  
In  chronic  infections,  persistent  antigenic  stimulation  along  with  impaired  
CD4  T  cell  function  leads  to  CD8  T  cell  exhaustion.  This  state  is  marked  
by  loss  of  CD8  T  cell  cytotoxic  functions,  TNF-
IFN-  with  dysfunctional  memory  T  cells  as  is  often  the  
case  in  chronic  HCV  infection37. 
4.2.3.  Evasion  of  Adoptive  Immune  Response  by  HCV 
 A  lot  of  theories  for  persistence  of  HCV  infection  are  hypothesized,  
but  the  following  three  mechanisms  have  substantial  experimental  support38. 
1.  Mutational  escape  of  viral  epitopes 
 The  error  prone  nature  of  the  viral  polymerase  generates  viral  variants  
capable  of  evading  cytotoxic  T  cells  and  neutralizing  antibodies. 
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2.  Functional  anergy  of  CD8  T  cells 
HCV  specific  CD8  T  cells  may  be  anergic  or  functionally  impaired  
in  chronic  infections. 
3.  Regulatory  T  cell  populations 
 Intrahepatic  CD8  T  cell  populations  producing  IL-10  are  known  to  
occur  in  chronic  infections.  IL-10  impairs  production  of  IFN  and  down  
regulates  effector  T  cell  responses. 
Mechanism  of  persistence 
Confection  with  HIV  and  schitosomiasis  have  been  associated  with  
viral  persistence  which  corresponds  with  a  diminished  CD4  lymphocyte  
response3.  The  highly  glycosylated  nature  of  the  viral  envelope  may  protect  
it  against  antibody  mediated  neutralisation.  The  envelope  may  have  evolved  
a  flexible  structure  that  serves  as  an  immunological  decoy  and  protects  an  
otherwise  vulnerable,  conserved  receptor  –  binding  ligand  from  antibody  
attack.  The  virus  may  downregulate  replication  to  a  level  that  is  too  low  
disrupting  cellular  homeostasis,  limiting  the  amount  of  viral  PAMPs  and  
antigens  produced.  HCV  sequence  variation  and  immune  escape  from  both  
T  cell  and  B  cell  may  also  contribute  to  viral  persistence.   
Mutation  within  the  amino  acid  sequence  of  a  critical  epitope  might  
permit  a  new  quasispecies  variant  to  escape  an  immune  response.  In  several  
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studies  acutely  infected  persons  who  developed  persistent  infection  had  a  
more  complex  quasispecies.   
Factors  affecting  disease  progression   
Many  factors  are  associated  with  increase  in  progression  of  the  disease.  
These  include  predilection  for  male,  elderly  age,  overweight,  intake  of  alcohol  
and  co-infection  of  HIV  and  HBV.     
HCV-HIV  co-infection 
HCV  infection  is  found  more  frequently  in  HIV  infected  persons  than  
in  general  population  because  of  a  common  mode  of  transmission.  The  
prevalence  of  HCV-  HIV  co-infection  also  markedly  varies  from  50-93%  in  
intravenous  drug  abuse  and  10%  in  homosexual  men  depending  on  the  route  
of  transmission.  Prevalence  of  HCV-HIV  co-infection  is  3.02%  in  Andhra  
Pradesh,  2.2%  in  Tamil  Nadu  ,  1.6%  in  Lucknow  and  1.06%  in  Vellore,  as  
reported  by  several  studies11,13,14,15. 
The  predominant  age  group  affected  was  41-50years  and  the  most  
prevalent  genotype  seen  in  HIV-HCV  co-infection  was  genotype  1b13.  Higher  
rate  of  HCV  RNA  was  found  in  HIV,  HCV  co-infection.   
HCV  -  HBV  co-infection 
Co-infection  of  HBV  in  the  proportion  of  HCV-infected  people  can  
have  an  effect  on  progression  of  hepatic  disease.  A  meta-analysis  showed  
that  HBV-HCV  co-infection  more  likely  to  cause  hepatocellular  carcinoma.   
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Modes  of  transmission 
The  common  routes  of  transmission  are  blood  transmission,  injection  
abuse,  unsafe  therapeutic  interventions  and  health  care  related  infections.  
Sexual  transmission  and  vertical  transmission  are  less  common  routes  of  
transmission. 
Blood  transmission 
Blood  transmission  is  the  major  mode  of  transmission.  Due  to  the  
mandatory  screening,  HCV  transmission  risk  is  low  in  developed  countries.  
In  developing  countries  blood  transfusion  is  a  common  cause  of  acquiring  
HCV  infection.  Blood  transfusion  allows  large  quantities  virions  to  enter  into  
the  blood.  Studies  have  shown  that  prevalence  of  HCV  is  below  2%  in  
voluntary  donors.  In  India  mandatory  HCV  screening  of  blood  and  blood  
products  was  introduced  in  2002.  Few  cases  of  infected  blood  donor  may  
be  missed  if  serological  tests  alone  are  used.   
V.  Gowri  et  al  study  in  Vellore  showed  sero-prevalence  of  HCV  
among  voluntary  blood  donor  is  0.13%11.   
Chandrasekaran  S  et  al  study  in  Madurai  showed  sero-prevalence  of  
HCV  among  voluntary  blood  donor  is  0.75%41. 
Unsafe  therapeutic  injections 
In  resource  limited  settings,  where  supply  of  sterile  syringes  may  not  
be  available  and  injection  are  administered  by  non-medical  personnel  outside  
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the  hospital.  Persons  who  receive  multiple  contaminated  injections  over  a  
period  of  time  increases  the  chance  of  acquiring  Hepatitis  C  Virus  infection. 
Intravenous  drug  use 
It  is  a  common  route  of  HCV  transmission  in  developed  countries.  
Highest  sero-prevalence  in  the  middle  age  group  seen  in  United  States  and  
Australia,  where  the  IVDs  have  been  the  predominant  mode  of  spread  for  
nearly  3  decades  which  constitutes  sixty  eight  percent  and  eighty  percent  of  
current  infections  respectively. 
Lopamundra  Ray  saraswati  et  al  study  observed  that  the  prevalence  
of  HCV  in  53.7  %,  and  co-infection  of  HIV  in  19.6  %  male  intravenous  
drug  abusers  in  Delhi  in  201219.   
In  a  study  by  Shruti  H.  Mehta  et  al  study  conducted  at  YRGCARE  
Chennai  1158  Intravenous  drug  users  were  screened  for  HCV  infection.  The  
study  reported  a  prevalence  of  55%.    Sharing  partners  are  necessary  for  
maintaining  transmission  of  HCV  than  other  any  other  blood-borne  viruses.   
HCV  is  ten  times  as  infectious  as  HIV,  per  unit  of  blood  evidence  shows  
that,  after  drying  at  room  temperature,  HCV  can  remain  infectious  for  about  
six  weeks  in  dried  blood  spots.  This  might  be  the  reason  for  the  constant  
spread  of  HCV  among  IVD’s.  This  could  be  due  to  unsafe  injection  practices  
like  sharing  equipment,  drawing  from  a  common  container  and  injecting  with  
used  needles. 
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Health  care  associated  infection 
  Occupational  transmission  of  HCV  infection  occurs  in  health-care  
workers  who  have  sustained  a  contaminated  needle  stick  injury  and  observed  
risk  of  transmission  in  these  circumstances  are  as  low  as  0·3%.   
Haemodialysis 
Patients  undergoing  haemodialysis  (HD)  have  a  higher  risk  of  acquiring  
HCV.  In  these  patients  infection  more  likely  to  become  chronic.  This  may  
be  responsible  for  transmission  of  HCV  in  dialysis  centres,  contributing  to  
the  increased  prevalence  of  HCV  among  haemodialysis  cases. 
Jaiswal  et  al  in  a  study  from  1992  to  2000  reported  prevalence  of  
30%21. 
Pragati  chigurupati  et  al  showed  a  prevalence  of  23.5%  in  HCV  
infection  among  the  hemodialysis  patients22.       
Sudrandrakumar  et  al’s  study  in  Coimbatore  showed  the  patients  on  
hemodialysis  had  12.4%  positivity  for  anti-  HCV  in  dialysis  unit.  Further,  
the  study  demonstrated  that  the  duration  of  haemodialysis  and  undergoing  
dialysis    at  more  than  one  centre  were  the  important  risk  factors  for  acquiring  
HCV  infection42. 
HCV  prevalence  in  HD  patients  was  found  to  be  4.3%  in  Delhi  and  
1.11%  in  Mangalore.  Gomes  M    et  al  study  observed  the  prevalence  of  anti-
HCV  was  13.3%  in  patients  who  had  HD  for  <1  year  in  comparison  to  
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69.9%  in  patients  who  had  HD  for  >10  years  -indicating  that  the  duration  
of  HD  is  related  to  a  higher  risk  of  developing  HCV  infection.   
Nosocomial  transmission,  prolonged  vascular  access,  risk  of  exposure  
to  infected  patients,  contaminated  equipment  and  sharing  of  multi-dose  
heparin  vials  are  some  factors  responsible  for  the  high  risk  in  HD  patients. 
The  clinical  outcome  HCV  in  haemodialysis  patients  vary  from  the  
general  population.  Hemodialysis  patients  will  have  a  milder  disease  with  
lower  liver  enzymes  and  viral  levels.  The  “silent”  clinical  course  is  results  
in  slower  disease  progression  and  a  lower  frequency  of  cirrhosis  and  
hepatocellular  carcinoma.  Possible  reasons  are  impaired  surveillance  leading  
to  a  less  aggressive  antibody  response  to  the  virus  and  intradialytic  release  
of  “hepatoprotective”  cytokines 
Sexual  transmission 
Sex  transmission  has  been  identified  as  minor  risk  factors  for  HCV  
transmission..  The  prevalence  of  HCV  infection  in  individuals  with  STDs  in  
in  South  India  was  6%. 
Vertical  transmission 
Mother  –child  transmission  is  estimated  to  occur  in  about  2·7–8·4%  
of  babies  born  to  HCV  infected  mothers.  New-born  born  to  HIV/HCV  co-
infected  mothers  have  higher  risk  of  acquiring  HCV  infection44. 
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Kumar  et  al  study  reported  a  prevalence  of  1.03  %  in  antenatal  
population43  while  the  results  of  other  studies  at  Shimla  and  Vellore  reported  
no  (0%)  prevalence.  The  timing  of  transmission  is  not  known.  The  
confirmation  of  HCV  transmission  is  based  on  detection  of  viral  RNA  or  
the  persistence  of  antibodies  after  18  months  of  age.  HCV  RNA  has  been  
detected  in  breast  milk.     
Diagnosis  of  HCV  infection 
Testing  for  infection  is  mainly  done  for  a  clinical  diagnosis  of  liver  
disease  in  symptomatic  individuals  and  as  a  part  of  mandatory  screening  in  
blood  banks  for  all  donors.  It  is  also  advisable  to  screen  people  who  are  at  
a  high  risk  for  the  HCV  infection.  Guidelines  recommend  HCV  screening  
should  be  done  in  persons  with  HIV  infection,  haemophilia,  haemodialysis,  
drug  abuse,  recipients  of  blood  transfusion  organ  transplant  before  1992;  
children  born  to  HCV  infected  mothers  and  health  care  workers45.  Diagnostic  
tests  are  broadly  classified  into  serological  assays  (indirect  tests),  detection  
of  HCV  RNA  and  core  antigen  (direct  tests). 
Serology 
Detection  of  HCV  specific  antibodies  is  an  indicator  of  infection,  not  
immunity.  Current  serological  assays  are  able  to  detect  HCV  5-  8  weeks  
after  the  onset  of  infection.  In  patients  who  clear  infection  spontaneously,  
HCV  antibody  may  remain  throughout  life,  decrease  slightly  and  gradually  
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disappear  after  several  years.  Anti-HCV  persists  indefinitely  in  patients  who  
develop  chronic  infection,  except  in  cases  of  profound  immunosuppression.   
Immuo-assays  are  based  on  enzymatic  reactions  like  ELISA  or  light  
emission  like  CLIA.  Different  generations  of  HCV  ELISA  detecting  
antibodies  to  different  recombinant  polypeptides  have  been  developed.  The  
first  generation  ELISA  target  a  part  of  NS4  region  of  HCV  genome.  The  
second  generation  target  a  part  of  NS4  and  protein  derived  from  NS3  and  
a  part  of  core(C-22).  The  third  generation  ELISA  detects  antibodies  against  
NS5  as  well.  It  has  a  high  sensitivity  of  about  97%.  Recombinant  immunoblot  
assay  (RIBA)  can  be  used  to  identify  the  specific  antibodies  against  individual  
HCV  antigens.     
Serological  assays  have  following  drawbacks: 
 False  negativity  in  the  window  period  between  entry  of  virus  and  the  
production  of  antibodies. 
 False  positivity  results  may  due  to  presence  of  non  specific  
immunoglobulins  that  can  bind  with  HCV  antigens. 
 False-negativity  can  occur  in  immunosuppressed  people  or  in  those  
who  are  undergoing  haemodialysis. 
According  to  CDC  person  be  considered  to  have  serologic  evidence  of  
HCV  infection  if  a  positive  result  of  anti-HCV  screening  is  confirmed  by  
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positive  results  of  a  further  test,  using  either  a  RIBA  or  NAT  to  detect  
HCV  RNA.    Rapid  immunoassay  helps  I  in  rapid  detection  of  antibody. 
HCV  core  Antigen  detection 
The  Core  antigen  can  be  present  in  infected  patients,  and  its  levels  
are  proportional  to  HCV-RNA.  Cost  of  Core  assays  is  less  than  molecular  
tests  46.  They  could  be  used  as  an  alternative  to  HCV-RNA  assays  in  the  
following  conditions: 
 To  differentiate  active  infection  from  resolved.   
 To  detect  antigen  in  the  window  period. 
 Detecting  infection  in  high-risk  seronegative  individuals. 
Molecular  assays 
Detection  of  viral  nucleic  acid 
Detection  of  HCV  RNA  is  necessary  to  establish  active  infection,  
either  acute  or  chronic,  as  well  as  for  monitoring  the  patients  on  treatment.  
real  time  RT-PCR,  transcription  mediated  amplification  (TMA),  and  branched  
DNA  testing  can  be  used.  Assays  that  detect  nucleic  acids  can  be  qualitative  
or  quantitative.   
Most  sensitive  test  for  detection  of  viral  load  is  quantitative  PCR.  
Most  precise  method  for  quantitation  is  branched-chain  DNA  test.    Molecular  
assays  have  excellent  specificities  98  to  99%  and  sensitivity  varying  from  
10  to  50  IU/ml45. 
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While  qualitative  methods  may  be  sufficient  for  screening  in  blood  
banks,  quantitative  assays  are  used  to  measure  the  baseline  viral  load  prior  
to  initiation  of  therapy,  and  then  at  specified  time  points  for  monitoring  the  
treatment  response  during  the  course  of  therapy.   
WHO  recommended  the  use  of  standard  international  units  (IU)  for  
the  measurement  of  the  viral  RNA  instead  of  viral  copies.  During  acute  
hepatitis,  the  delay  in  the  appearance  of  anti-HCV  hampers  acute  phase  
diagnosis.  The  early  detection  of  HCV  RNA  in  peripheral  blood  confirms  
the  diagnosis  and  opens  up  therapeutic  possibilities.  In  chronic  hepatitis,  the  
diagnosis  of  sero-negative  forms  may  only  be  resolved  by  PCR.  Moreover,  
the  presence  of  HCV  RNA  in  peripheral  blood  represents  the  only  marker  
of  ongoing  viral  replication  and  coincides  with  the  hepatic  damage.  During  
treatment  with  interferon,  the  follow  up  of  HCV  RNA  sequences  makes  it  
possible  to  monitor  its  efficacy.   
The  search  for  HCV  RNA  sequences  directly  in  liver  tissue  shows  
that  HCV  may  multiply  in  the  hepatocytes  in  the  absence  of  virus  in  the  
circulation.  The  demonstration  of  HCV  RNA  in  the  hepatocytes  in  the  liver  
transplanted  patients  is  essential  for  etiological  diagnosis.  Epidemiological  
study  using  PCR  is  a  major  tool  for  documenting  vertical  transmission  
between  mother  and  child.  PCR  is  important  for  the  analysis  of  the  HCV  
genome. 
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Viral  genotyping 
Determination  of  genotype  of  the  infecting  virus  is  necessary  to  assess  
the  probability  of  response.  It  also  helps  in  deciding  the  duration  of  treatment.  
Genotyping  can  be  done  by  sequencing  either  the  5’UTR/core,  NS3  or  the  
NS5b  region  of  HCV  genome.  A  number  of  assays  are  available  for  the  
same  and  include  real  time  PCR  with  genotype  specific  probes  and  primers  
reverse  hybridization  of  PCR  products  into  genotype  specific  probes  coated  
on  solid  supports  (line  probe  assays),  PCR-RFLP,  where  the  PCR  products  
are  digested  with  restriction  enzymes,  to  obtain  fragments  of  varying  length  
depending  on  the  genotype. 
Liver  function  Tests: 
Liver  function  tests  are  done  to  assess  liver  function.  The  tests  done  
are  aminotransferases,  alkaline  phospatase,  serum  bilurubin,  serum  proteins,  
prothrombin  time  and  APTT. 
Treatment  of  Hepatitis  C  infection 
Hepatitis  C  is  a  severe  infection  causing  considerable  morbidity  and  
mortality.  The  main  concern  is  progression  to  liver  cirrhosis  and  its  
accompanying  complication.  Patients  with  chronic  infection  are  also  at  risk  
of  extrahepatic  manifestations  even  in  the  absence  of  progressive  fibrosis,  
some  of  which  may  be  severe. 
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Antiviral  treatment  is  necessary  to  prevent  both  hepatic  as  well  as  
extrahepatic  sequelae  of  infection.  Virological  care,  marked  by  sustained  lack  
of  viraemia  six  months  after  completion  of  treatment,  associated  with  decrease  
in  liver  inflammation,  as  evidenced  by  stabilised  enzyme  levels  and  decreased  
rate  of  progression  of  fibrosis  indicates  good  prognosis.   
Timely  treatment  has  been  shown  to  decrease  the  development  of  end  
stage  liver  disease,  need  for  liver  transplantation,  hepatocellular  carcinoma  
rates  and  liver  related  morbidity.  The  Presence  of  non-modifiable  factors,  
genotype  1,  a  heavy  viral  load,  overweight,  ethnic  race,  older  age,  and  
fibrosis,  indicates  poor  therapeutic  response.  Sustained  virological  response  
helps  is  assessing  therapeutic  response. 
The  primary  aims  of  anti-HCV  therapy  for  chronic  hepatitis  C  cases  
are  prevention  of  progression  to  cirrhosis  and  development  of  HCC.  A  
combination  of  pegylated  interferon  and  ribavirin  cures  HCV  in  about             
40%  to  50%  of  untreated  patients  with  genotype  1b.  In  patients  achieving  
SVR,  in  interferon  therapy  has  improved  liver  fibrosis.   
However,  only  limited  numbers  of  patients  show  beneficial  antiviral  
effects  of  Interferon  based  therapy.  The  effect  depends  on  the  patient’s  
genetic  background,  presence  of  hepatic  fibrosis,  age,  HIV  co-infection,  and  
other  factors.  In  addition,  IFN-based  therapy  has  some  adverse  effects  that  
may  lead  to  poor  drug  adherence  or  treatment  discontinuation. 
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Recently,  direct-acting  antiviral  (DAA)  regimens  have  been  approved  
for  treatment.  The  first-generation  protease  inhibitors  telaprevir  (TVR)  and  
boceprevir  (BOC)  were  approved  as  DAA  combination  therapy  with  Pegylated  
Interferon  and  Ribavarin.  Although  triple  therapy  achieves  a  higher  SVR  rate  
than  does  conventional  IFN-based  therapy,  treatment  is  associated  with  severe  
adverse  effects.  Due  to  the  development  of  new  DAAs  with  better  safety  
and  stronger  antiviral  effects,  it  is  expected  that  almost  all  patients  with  
HCV  infection  will  achieve  SVR. 
HCV  vaccine 
Development  of  HCV  vaccine  is  most  challenging  and  several  factors  
that  hinder  the  development  of  vaccine  are: 
1. Presence  of  genetic  diversity  among  isolates  (six  genotypes,  >100  
subtypes). 
2. Production  of  quasispecies  within  an  individual  due  to  mutation  in  the  
HVR1  region  of    structural  E2  gene. 
3. Poorly  defined  immunological  correlates  of  protection  and  finally, 
4. Inability  to  propagate  in  culture  to  isolate  the  virus. 
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MATERIAL  AND  METHODS 
Study  design 
This  prospective  study  was  conducted  in  the  Department  of  
Microbiology,  Coimbatore  Medical  College,  Coimbatore  over  a  period  of  12  
months  from  August  2015  to  July  2016.   
Blood  samples  were  collected  from  200  patients  admitted  with  chronic  
liver  disease  for  detecting  Hepatitis  C  virus  infection  in  various  clinical  
departments  of  Coimbatore  Medical  College  hospital. 
Ethic  approval 
The  approval  for  this  study  was  obtained  from  the  ethical  committee  
prior  to  its  conduct.    Informed  consent  was  obtained  from  the  patients/  
guardian  of  the  patients 
Inclusion  criteria: 
 Patient  with  chronic  hepatitis   
 Fulminant  hepatitis 
 Hepatic  failure 
 Cirrhosis  of  Liver 
 Hepatocellular  carcinoma 
 Persistently  elevated  Liver  enzymes,  Serum  bilirubin  >  6  months 
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Exclusion  criteria   
 Patients  with  acute  hepatitis 
 Auto  immune  diseases  of  liver 
 Inborn  errors  of  metabolism       
 Systemic  diseases  affecting  liver  function   
 Hepatic  congestion  due  to  cardiac  failure 
 Drug  induced  hepatic  dysfunction 
The  patient  name,  age,  sex,  address,  Inpatient/outpatient  number  and  
detailed  clinical  history  were  noted.  General  and  systemic  examination  was  
carried  out. 
Ten  ml  of  blood  was  withdrawn  aseptically  by  venepuncture.    The  5ml  
blood  sample  for  serum  was  transferred  to  plain  tube  (clot  activator)  for  
Anti  HCV  ELISA.  The  5ml  blood  sample  for  plasma  was  collected  in  a  
vacutainer  tubes  containing  K2EDTA  and  the  tube  was  centrifuged  at   
3000rpm  for  10  minutes  for  separation  of  plasma.  This  was  stored  at  -  20°C  
for  PCR.  ELISA  test  for  HCV  antibody  is  performed  using  Hepascan  kit  as  
per  manufacturer  instruction  and  samples  is  tested  for  detection  of  HCV-
RNA  by  reverse  transcription  and  real  time  polymerase  chain  reaction           
(RT-PCR).  Genotyping  of  the  positive  samples  were  done  out  by  real  time  
RT-PCR. 
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METHODOLOGY 
Chronic  liver  disease  patients 
 
10  ml  of  Blood  collected  (2  samples,  5ml  each) 
 
Plasma  sample  (K2EDTA)                      Serum  sample 
 
HCV  RNA  by  real  time  RT-PCR                             Anti-  HCV  by  ELISA 
 
Positive   Negative                   Positive       Negative 
 
Genotyping  by  PCR  by  real  time  RT-PCR 
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Procedure  for  Anti  HCV  ELISA 
Detection  of  HCV  infection  usually  begins  with  serological  testing  to  
detect  anti  HCV  antibodies. 
The  HCV  ELISA 
The  HCV  ELISA  TEST  (Hepa-scan)  is  an  indirect  antibody  Enzyme  
immuno  absorbent  assay  for  the  invitro  detection  of  antibodies  to  HCV  in  
human  plasma  and  serum.  It  is  a  third  generation  test,  uses  a  greater  range  
of  antigens  from  core,  NS3,  NS4  and  NS5  regions  of  the  virus  to  selectively  
detect  all  sub  types  of  hepatitis  virus  in  human  plasma  or  serum  with  high  
degree  of  sensitivity  and  specificity.   
Requirements: 
 Microtiter  plate 
 Dilution  buffer 
 Wash  solution 
 Horse  radish  peroxidase  conjugate 
 Tetra  methyl  benzidine  substrate 
 Tetra  methyl  benzidine  diluent 
 Stop  solution 
 Positive  control 
 Negative  control 
 Micropipettes   
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 Plastic  sealer,   
 ELISA  reader   
Procedure: 
 The  microtitre  wells  are  fitted  in  the  frame  provided  and  labelled.   
 Well  A1  is  marked  as  blank,  B1,  C1  marked  as  negative  control  and  
D1,  E1,  F1  as  positive  control. 
 100µl  of  ready  to  use  controls  are  added  to  corresponding  wells.  
100µl  of  dilution  buffer  and  10  µl  of  samples  are  added.   
 The  microtitre  plate  is  incubated  for  30minutes  at  room  temperature  
(25-30ºC).   
 Wells  are  washed  5  times  with  working  wash  buffer.   
 100  µl  of  working  HRP  conjugate  is  added  to  each  well  and  incubated  
for  30minutes  at  room  temperature  (25-30ºC).   
 Wells  are  washed  5  times  with  working  wash  buffer.   
 100  µl  of  working  TMB  substrate  is  added  to  each  well. 
   Plate  is  incubated  for  30minutes  at  room  temperature  (25-30ºC).   
 100µl  of  stop  solution  is  added.   
   The  absorbance  is  read  at  450/630nm  wavelength. 
Cut  off  formula:  (0.1×PC)  +  0.1 
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Validation: 
Control Value 
Blank <  0.15 
Negative  control <  0.25 
Positive  control >0.60 
 
Procedure  for  HCV  PCR: 
Principle  of  real  time  PCR  is  based  on  the  amplification  of  specific  
regions  of  the  viral  genome  detection  of  amplified  product  via  fluorescent  
dyes.  Specific  fluorescent  dyes  linked  to  oligonucleotide  probes  which  bind  
to  the  amplified  product.  Detection  and  quantitation  of  the  accumulating  
product  is  by  monitoring  fluorescent  signal  during  PCR  run  without  having  
to  re-open  the  reaction  tubes  after  the  PCR  run.  First  step  in  real  time  PCR  
is  reverse  transcription  step.  Primers  were  designed  to  amplify  a  240  bp  
fragment  within  the  5’  non-coding  region  of  the  HCV  genome.   
Requirements: 
 RNA  isolation  kit 
 Pipettes  (adjustable) 
 Sterile  pipette  tips  with  filters   
 Vortex  mixer 
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 Benchtop  centrifuge 
 Bio  –  Rad  thermo  cycler 
 Strip  Tubes  and  Caps   
 Cooling  block   
RNA  Extraction: 
KIT:    Qiagen  extraction  kit 
Components: 
 QIA  amp  Mini  Spin  Columns 
 Collection  Tubes  (2ml) 
 AVL  lysis  buffer 
 Molecular  grade  ethanol   
 Aqueous  wash  buffer  1 
 Aqueous  wash  buffer  2 
 Elution  buffer  (AVE)   
 Carrier  RNA  (poly  A) 
Internal  control  is  used  to  monitor  the  RNA  isolation  procedure  and  
PCR  inhibition. 
Preparation  of  reagents: 
Carrier  RNA:  310µl  of  Buffer  AVE  is  added  to  a  vial  of  carrier  RNA 
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Buffer  AVL:  310  µl  of  prepared  RNA  mixed  to  a  bottle  of  Buffer  
AVL  (31ml),  stored  at  4ºC 
Buffer  AW1:  125  ml  of  Ethanol  is  added  to  a  bottle  of  95ml  Buffer  
AW1 
Buffer  AW2:  160  ml  of  Ethanol  is  added  to  a  bottle  of  66ml  Buffer  
AW2 
RNA  extraction  Procedure 
 560  µl  of  Buffer  AVL  is  added  into  1.5ml  specimen  tube.   
 140  µl  of  the  specimen  transferred  to  AVL  buffer  tube,  mixed  well,  
Vortexed  and  Incubated  for  10  minutes  at  ambient  temperature.   
 560  µl  of  ethyl  alcohol  is  added  to  the  sample.   
 630  µl  from  mixture  is  added  to  the  QIAmp  spin  column  and  
Centrifuged  for  one  minute  at  8000rpm. 
 Collection  tube  is  removed  and  spin  column  is  transferred  to  a  new  
2  ml  tube.   
 Remaining  630  µl  of  the  above  solution  is  added  and  centrifuged  for  
one  minute  at  8000rpm.   
 Collection  tube  changed  and  the  spin  column  is  fixed  in  a  new  tube.   
 500  µl  of  AW1  is  added  and  centrifuged  for  1  minute  at  8000rpm.   
 Tube  containing  filtrate  is  discarded  and  the  spin  column  is  transferred  
to  new  tube. 
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   500  µl  of  Buffer  AW2  is  added  and  centrifuged  for  3  minutes  at  
14000rpm.   
   The  spin  column  is  fixed  in  a  1.5  ml  Microfuge  tube  with  cap.  60  
µl  of  Buffer  AVE  is  added  and  kept  in  a  room  temperature  for  one  
minute.   
   Centrifuged  for  8000rpm  for  1  minute  to  elute  RNA 
Internal  control: 
The  internal  control  is  added  in  the  isolation  procedure  at  a  ratio  of  
  per    elution  volume  or  directly  to  the  mixture  of  Hep.  C  Virus  RG  
Master  A  and  Hep.  C  Virus  RG  Master  B  to  check  PCR  inhibition. 
Nucleic  acid  amplification  by  real  time  RT-PCR: 
HCV  RNA  detection  is  done  by  real  time  RT-PCR,  which  is  based  
on  Taqman  principle.  During  PCR  forward  and  reverse  primers  hybridize  to  
a  specific  sequence  product.  Taqman  probe,  is  contained  in  the  same  reaction  
mixture,  which  consists  of  an  oligonucleotide  labelled  with  a  5’-reporter  dye  
and  a  downstream,  3’-quencher  dye.  It  hybridizes  and  possesses  5’-3’  
exonuclease  activity  cleaves  the  probe.  The  reporter  and  quencher  dye  are  
separated  upon  cleavage,  resulting  in  an  increase  in  fluorescence  for  the  
reporter.  Thus,  the  increase  in  fluorescence  is  directly  proportional  to  the  
target  amplification  during  PCR. 
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PCR  KIT:   
Qiagen’s  Artus  HCV  RG  RT-  PCR  Kit  
Number  of  reactions  :  24 
Contents: 
 Hep.  C  Virus  RG  Master  A 
 Hep.  C  Virus  RG  Master  B 
 Hep  C  Virus  RG  QS  1*(104IU/µl) 
 Hep  C  Virus  RG  QS  2*(103IU/µl) 
 Hep  C  Virus  RG  QS  3*(102IU/µl) 
 Hep  C  Virus  RG  QS  4*(101IU/µl) 
 Hep  C  Virus  RG  IC 
 Water  (PCR  Grade)    
Storage  and  stability: 
The  components  of  the  Artus  HCV  RG  RT-PCR  Kit  were  stored  at  
–30°C  to  –15°C.   
Real  time  RT-PCR  procedure: 
Required  number  of  PCR  tubes  placed  in  thee  adapters  of  the  
precooled  block  that  includes  tubes  for  extracted  samples,  PC  and  atleast  
one  NC  (PCR  grade  water).  All  samples  are  thawed  completely  and  mixed  
well.   
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Preparation  of  reaction  mix/run 
Hep.  C  Virus  RG  Master  A   -  12µl 
Hep.  C  Virus  RG  Master  B      -  18  µl 
Hep  C  Virus  RG  IC       -  2  µl 
Total  volume        -  32µl 
Preparation  of  PCR  assay/run 
Master  Mix      -  30  µl 
Sample      -  20  µl 
Total  volume  (Reaction  volume) -  50  µl 
 30  µl  of  the  master  mix  is  added  into  each  PCR  tube. 
 20  µl  eluted  sample  RNA  is  added. 
 One  of  the  quantitation  standards  must  be  used  as  positive  control   
 20  µl  of  water  is  added  as  a  negative  control.   
 PCR  tubes  are  placed  in  thermocycler. 
Programming  thermocycler  (Bio-Rad)  for  PCR  amplification 
Reverse  transcription  -  50ºC  for  30Minutes 
Taq  inhibitor  activation   -  95  ºC  for  15minutes 
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Cyclic  conditions  (50  cycles) 
Denaturation   -  95  ºC  for  30seconds 
Annealing   -  50  ºC  for  60seconds 
Extension     -  72  ºC  for  30seconds 
PCR  amplification  steps: 
Reverse  transcription: 
The  RNA  template  is  converted  into  cDNA  using  a  reverse  
transcription.   
Denaturation:   
The  first  step  in  the  amplification  procedure  is  denaturation.  The  
thermocycler  raises  the  temperature  to  95ºC  for  30seconds  for  Taq  enzyme  
activation.  The  hydrogen  bonds  holding  the  complimentary  strands  of  DNA  
together  are  broken.   
Annealing: 
When  temperature  is  decreased  to  50  ºC  for  60  seconds  the  
complementary  binding  of  the  two  specific  oligonucleotide  primers  to  the  
DNA  template  take  place. 
Extension: 
The  DNA  polymerase  extends  the  primers  when  the  temperature  is  
increased  to  72  ºC  for  30  seconds.  The  template  DNA  is  synthesised  using  
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deoxynucleotides  in  the  mixture.  The  template  plate  DNA  and  newly  
synthesised  complementary  DNA  strands  join  together  to  form  new  double  
stranded  DNA  copies.  The  newly  formed  DNA  copies  acts  as  a  template  
for  further  amplification.  The  reaction  product  of  each  cycle  was  detected  
using  fluorescence  signal.   
Interpretation:   
 No  HCV  RNA  is  detectable  -  No  signal  is  detected  in  fluorescence  
channel  Cycling  A.  FAM  (Green),  with  positive  signal  from  the  
internal  control  in  the  Cycling  Orange  channel.   
 HCV  RNA  detectable-  A  signal  is  detected  in  fluorescence  channel  
Cycling  A.  FAM  (Green),  ROX  (orange)  -  The  result  of  the  analysis  
is  positive. 
 Result  cannot  be  concluded  when  the  signal  is  not  detected  in  both  
channels 
HCV  genotyping  by  real  time  RT-  PCR: 
Kit:  Geno  Sen’  HCV  1/2/3/4  (Rotor  Gene)  Qualitative  Real  Time  PCR  Kit 
Contents: 
 HCV  Genotyping  Super  mix(R1) 
 HCV  Genotyping  Mg  sol  RT  (R2)   
 HCV  Genotyping  Positive  control  (  only  Genotype  1,2,3,4) 
 Molecular  grade  water   
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Procedure: 
Required  number  of  PCR  tubes  placed  in  the  cooling  block.  All  
reagents  and  samples  are  thawed  completely  before  use  and  mixed  by  
pipetting. 
HCV  Genotyping  Master  Mix  preparation 
HCV  Genotyping  Super  Mix   -15µl 
HCV  Genotyping  Mg.  Sol    -  5  µl 
Total  volume  (Reaction  volume) -  20  µl 
 20  µl  of  Master  Mix  added  into  each  labelled  PCR  tube.   
 30  µl  extracted  sample  RNA  positive  control  and  Water  (PCR}  as  a  
negative  control  is  added  into  the  corresponding  tubes.   
 PCR  tubes  are  closed  and  transferred  to  rotor  of  the  Rotor  Gene  
instrument. 
Cyclic  condition: 
Reverse  Transcription    -  50ºC  for  15  minutes 
Taq  inhibitor  activation   -  95º  for  10  minutes 
PCR  amplification 
Number  of  cycles  -45 
Denaturation            -  95ºC  for  15  seconds 
Annealing                -  55ºC  for  20  seconds 
Extension                   -  72ºC  for  15  seconds 
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Interpretation: 
 HCV  Genotype  1-  Signal  is  detected  in  fluorescence  channel  cycling  
A.  Red. 
 HCV  Genotype  2  -  Signal  is  detected  in  fluorescence  channel  cycling  
A.  Green   
 HCV  Genotype  3-  Signal  is  detected  in  fluorescence  channel  cycling  
A.  Orange  –   
 HCV  Genotype  4  -  Signal  is  detected  in  fluorescence  channel  cycling  
A.  Yellow  –   
 If  signal  is  not  detected  in  any  of  the  above  fluorescence  channel  
cycling-  Genotype  other  than  1,2,3,4. 
 If  signal  is  not  detected  in  fluorescence  channel  cycling  A.  Green,  
Yellow,  Orange,  and  Red  for  samples  and  positive  control–
Troubleshooting.  Repeat  the  assay. 
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FIG 5: QIAGEN HCV RNA PCR KIT 
 
 
FIG 6: THERMAL CYCLER – BIO RAD  CFX96 REAL TIME SYSTEM  
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RESULTS 
Description  of  study  population: 
200  patients  with  clinical,  biochemical  and  ultrasonographic  evidence  
of  chronic  liver  disease  enrolled  in  the  present  study.  The  study  group  
comprised  of  61  cases  of  chronic  hepatitis,  133  cases  of  cirrhosis  and  6  
cases  of  hepatocellular  carcinoma. 
Age  distribution: 
The  age-wise  distribution  of  the  patients  in  the  study  group  ranges  
from  21  to  70  years  ,  with  a  mean  of  45.  The  majority  of  the  cases  belong  
to  age  group  between  41  to  70  years  (76.5%).  Age  of  the  patients                           
(Refer  table:1) 
Gender  distribution 
Among  200  patients  under  study  group,  110(55%)  were  males  and  
90(45%)  were  females  respectively  (Refer  table:  2) 
Serological  profile  of  study  population: 
The  serological  assay  was  done  for  detection  of  Anti-HCV  antibodies.  
Out  of  200  patients  tested  for  Anti-HCV  antibodies  by  ELISA,  56(28%)  
were  positive.  (Refer  table  no:  3) 
Out  of  61  cases  of  Chronic  Hepatitis,  14  (22.9%)  and  from  133  cases  
of  cirrhosis  38  (28.6%)  were  positive  for  Anti-  HCV  antibodies  by  ELISA. 
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Age  specific  distribution: 
Age-wise  analysis  in  the  present  study  showed  high  sero-  positivity  
among  individuals  in  the  age  group  of  31-40  years  (31.8%)  followed  by  age  
group  41-50  years  (30.1%)  and  51-70  years  (27%).  Lowest  prevalence  
observed in age group  greater  than  70  years  (15.3%)  and  21-30  years  (16.67%).  
(Refer  table  no  4) 
Gender  distribution: 
Among  the  56  Anti-HCV  positive  patients,  33(30.8%)  and  23(24.7%)  
were  males  and  females  respectively.  (Refer  table  5) 
Liver  enzyme  profile: 
Liver  enzymes  in  HCV  related  chronic  liver  disease  are  may  be  
fluctuating  or  normal.  In  the  present  study  showed  ALT  was  elevated  in  
35.7%,  AST  in  30.35%  and  Alkaline  phosphatase  in  33.9%  of  Anti-HCV  
positives. 
The  present  study  also  showed  that  serum  bilirubin  was  elevated  only  
in  2.8%  of  Anti-HCV  positives.  (Refer  table  7) 
Risk  factors  distribution: 
In  the  present  study,  the  probable  risk  factor  for  HCV  transmission  
was  observed  as  blood  transfusion  due  to  non-surgical  causes  in  11  cases  
(29.7%),  surgery  and  blood  transfusion  in  8  cases  (19%),  haemodialysis  in  
5  cases  (23.8%),  unsafe  injection  in  6  cases  (19%)  and  IV  drug  abuse  in  
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only  one  case  (33%).  No  risk  factors  were  identified  in  other  Anti-HCV  
positive  cases  (40%).  (Refer  table  8) 
Molecular  assay: 
Out  of  200  samples  tested  for  the  presence  of  HCV  RNA  by  real  
time  only    RT-PCR,  29  (14.5%)  were  detected  to  have  HCV  RNA.  26(13%)  
samples  had  been  found  to  be  positive  by  both  ELISA  and  PCR.  Among  
144  ELISA  negative  samples,  3  (2.1%)  were  PCR  positive.  Thirty  ELISA  
positive  samples  were  tested  negative  by  PCR.  (Refer  table  9) 
Genotype  distribution: 
All  the  HCV  RNA  positive  samples  were  subjected  to  genotype  
determination  by  real  time  RT-PCR.  Genotype  3  was  most  common  type  
observed  in  17(58.6%)  in  this  study  followed  by  the  genotype  4  which  was  
seen  in  6  (20.6%)  cases.  Four  cases  (13.7%)  showed  genotype  1  and  genotype  
other  than  1,2,3,4  was  also  observed  in  2  (6.9%)  cases.  (Refer  table  10) 
Genotype  3  is  the  more  prevalent  genotype  in  the  age  group  31  –  70  years  
and  also  in  both  genders  (Refer  table  12) 
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TABLE:  1 
AGE-WISE  DISTRIBUTION  OF  STUDY  POPULATION 
Age  group(in  years) Number  of  patients 
(n=200) 
Percentage 
21-30 12 6% 
31-40 22 11% 
41-50 53 26.5% 
51-60 48 24% 
61-70 52 26% 
>70 13 6.5% 
 
TABLE:  2 
GENDER-WISE  DISTRIBUTION  OF  STUDY  POPULATION 
GENDER NUMBER  OF  
PATIENTS   
PERCENTAGE 
MALE 110 55% 
FEMALE 90 45% 
TOTAL 200 100% 
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TABLE  NO:  3 
SERO-PREVALENCE  OF  HCV  AMONG  CHRONIC  LIVER  DISEASE  
PATIENTS 
No  of    chronic  liver  
disease  patient 
No  of  Anti-HCV  
positive  cases 
(by  ELISA) 
Percentage 
200 56 28% 
 
TABLE  NO:  4 
AGE-  WISE  DISTRIBUTION  OF  ANTI-HCV  POSITIVE  CASES 
Age  groups No  of  cases 
(n=200) 
ELISA  positive 
cases 
21-30yrs 12 2(16.67) 
31-40yrs 22 7(31.8%) 
41-50yrs 53 16(30.1%) 
51-60yrs 48 13(27%) 
61-70yrs 52 14(26.9%) 
>70yrs 13 2(15.3%) 
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TABLE:  5 
GENDER  DISTRIBUTION  OF ANTI-  HCV  POSITIVE  CASES  (n=200) 
Gender No  of  cases Anti-  HCV  positive  
cases 
Male 110 33(30%) 
Female 90 23(25.5%) 
 
TABLE:  6 
DISTRIBUTION  OF  ANTI-HCV  AND  PCR  POSITIVE  CASES  
BASED  ON  CLINICAL  PRESENTATION 
Clinical  
presentation 
No  of  cases 
(n=200) 
ELISA  positive 
Cases 
PCR  positive 
Cases 
Chronic  hepatitis 61 14(22.9%) 8(13%) 
Cirrhosis 133 38(28.6%) 18(13.5%) 
Hepatocellular  
carcinoma 
6 4(66.7%) 3(50%) 
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TABLE:  7 
BIOCHEMICAL  PROFILE  IN  ANTI-HCV  POSITIVE  CASES  (n=56) 
LIVER  ENZYME Normal Elevated 
Alanine  
aminotransferase(ALT) 
36  (64.2%) 20  (35.7%) 
Asparate  
aminotransferase(AST) 
39(69.65%)  17(30.35%) 
Serum  alkaline  
phosphatase 
37(66.1%) 19(33.9%) 
Serum  Bilirubin 32(57.14%) 24(42.8%) 
 
TABLE:  8 
DISTRIBUTION  BASED  ON  PROBABLE  HISTORY  OF  EXPOSURE  
TO  HCV  INFECTION 
RISK  FACTOR No  of  cases 
(n=200) 
No  of  Anti-  
HCV  
Positive  
cases 
NO  of  HCV  
RNA  Positive  
cases   
Blood  transfusion  due  
to  non-surgical  cause 
37 11  (29.7%) 4(10.8%) 
Haemodialysis 21 5(23.8%) 4(19%) 
Surgery  and  Blood  
transfusion 
42 8(19%) 5(12%) 
Unsafe  injection 32 6(19%) 1(3.1%) 
IV  drug  abuse 3 1(33%) - 
Unknown 65 26(40%) 15(23.1%) 
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TABLE  NO:  9 
COMPARISION  OF  RESULTS:  ELISA  AND  PCR  (n=200) 
Result ELISA  +ve 
Cases 
  PCR  +ve 
cases 
Both    +ve 
cases 
No % No % No % 
Positive 56 28% 29 14.5% 26 13% 
Negative 144 72% 171 85.5% 141 70.5% 
 
 
TABLE:  10 
PREVALENCE  OF  HCV  GENOTYPES  AMONG  CHRONIC  LIVER  
DISEASE  PATIENTS 
Genotype Genotype  1 
Genotype  
2 
Genotype  
3 
Genotype  
4 
Genotype  other  
than  1,2,3,4 
No  of  
cases(n=29) 
4(13.7%) 0(0%) 17(58.6%) 6(20.6%) 2(6.9%) 
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TABLE:  11 
PREVALENCE  OF  HCV  GENOTYPES   
AMONG  VARIOUS  AGE  GROUPS 
Age  
groups 
Genotype  
1 
Genotype  
3 
Genotype  
4 
Genotype  
other  than  
1,2,3,4 
Total 
21-30yrs 0 0 2 0 2 
31-40yrs 0 3 1 0 3 
41-50yrs 1 5 3 0 9 
51-60yrs 1 2 0 1 4 
61-70yrs 2 7 0 1 10 
Total 4 17 6 2 - 
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TABLE:  12 
GENDER  BASED  DISTRIBUTION  OF  HCV  GENOTYPES   
 
Genotype 
 
Male 
 
     Female 
Genotype  1 1(25%) 3(75%) 
Genotype  2 - - 
Genotype  3 10(58.8%) 7(41.2%) 
Genotype  4 5(83%) 1(16%) 
Genotype  Other  than  
1,2,3,4 
1(50%) 1(50%) 
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CHART 5 
GENDER DISTRIBUTION OF ANTI- HCV POSITIVE CASES (n=200) 
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CHART 7 
BIOCHEMICAL PROFILE IN ANTI-HCV POSITIVE CASES (n=56) 
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DISTRIBUTION BASED ON PROBABLE HISTORY OF                                  
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CHART 9 
COMPARISION OF RESULTS:  ANTI-HCV ELISA AND                                              
HCV RNA PCR (n=200) 
 
CHART 10 
PREVALENCE OF HCV GENOTYPES AMONG 
 CHRONIC LIVER DISEASE PATIENTS 
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CHART 11 
PREVALENCE OF HCV GENOTYPES AMONG VARIOUS AGE GROUPS 
 
CHART 12 
GENDER BASED DISTRIBUTION OF HCV GENOTYPES  
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DISCUSSION 
Hepatitis  C  virus  infection  is  a  serious  threat  to  health  care  system.  
It  can  cause  varying  clinical  conditions  ranging  from  acute  infection  to  
chronic  hepatitis  and  hepatocellular  carcinoma.  The  sero-prevalence  of  HCV  
varies  in  different  parts  of  the  country.  The  complex  and  uncertain  nature  
of  HCV  infection  and  its  chronicity  emphasises  the  difficulties  in  prevention  
and  control  of  HCV. 
The  information  about  sero-prevalence  of  HCV  among  chronic  liver  
disease  cases  and  relative  distribution  of  each  genotype  are  essential  tool  to  
formulate  effective  treatment  strategies. 
In  this  study,  200  chronic  liver  disease  cases  were  included  as  study  
population.  Patient  selection  was  based  on  clinical,  biochemical  and  
ultrasonographic  evidence  of  chronic  liver  disease.  The  patients  were  
subjected  to  serological  test  for  detecting  antibodies.  Detection  of  HCV  RNA  
&  genotyping  is  done  by  molecular  assay. 
In  the  present  study,  200  CLD  patients  were  screened  and  56  (28%)  
were  tested  positive  for  Anti-HCV  antibodies.  The  prevalence  among  chronic  
liver  disease  patients  has  been  high  when  compared  with  general            
population  (0.87%)17.  This  sero-prevalence  rate  is  comparable  with  the  sero-
prevalence  of  Anti-HCV  18%  by  Anirban  Kundu  et  al  (2013)  and  22.5%  
by  Abel  Girma  Ayele  et  al  (2015),  and  26%  Issar  SK  et  al  (1995)  and  other  
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studies  reported  previously50,51,52,53. This implies that there has been no  
appreciable change in the  sero-prevalence  of  HCV  over  the  last  10  year  period. 
Much  lower  sero-prevalence  of  4%  was  observed  by  Sanjay  Sharma  et  al  
(2006),  5.7%  by  A  Blankson  et  al  (2005),  and  8.2%  observed  by  Ganesh  
Kumar  Anbazhagan  et  al  (2010)57,  60,  61,.    In  relation  to  variation  of  HCV  
sero-prevalence,  the  reasons  cannot  be  completely  discerned.  However,  the  
difference  in  demographic  characteristics  of  the  study  population,  the  
difference  in  hepatitis  epidemiology,  awareness  of  the  routes  HCV  
transmission,  efforts  made  to  implement  universal  precautions  by  health  
professionals  and  preliminary  benefits  due  to  the  mandatory  HCV  screening  
while  blood  donation  and  prior  to  any  surgical  procedure  might  explain  these  
discrepancies.   
The  majority  of  the  CLD  cases  belong  to  age  group  31-70  (76.5  %).  
Sero-prevalence  was  highest  among  persons  in  the  age  group  31-50  years  
(30.6%)  and  a  substantial  prevalence  till  70  years  of  age.  This  finding  goes  
in  correlation  with  study  done  by  Sandhu  et  al  (2015)71  and  Ganesh  Kumar  
Anbazhagan  et  al  (2010)61.    The  lowest  prevalence  was  observed  in  the  age  
group  of  less  than  20  years  (16.67%)  and  more  than  70  years  (15.3%)  which  
is  comparable  to  the  other  studies  by  Soin  et  al  (2015)57,  Paramdeep  Singh  
et  al  (2014)74.  This  sero-prevalence  pattern  of  high  age  distribution  i.e.,  after  
3rd  decade  of  life  indicates  that  the  HCV  transmission    would  have  either  
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occurred  in  their  early  childhood  or  during  the  adulthood  period  .  The  
chronic  HCV  infection  may  lead  to  progression  of  liver  diseases.    Now,  it  
may  end  up  with      Cirrhosis,  CLD  &  HCC  over  a  period  of  20-  40  years.   
Regarding  gender  of  Hepatitis  C  positive  patients,  this  study  has  shown  that  
there  were  33  (30.8%)  males  and  23  (24.7%)  females  showing  predominance  
of  male  gender.  Similar  findings  were  reported  by  Atreyi  Chakraborty  et  al  
(2015)  study58.  It  showed  significantly  higher  prevalence  in  male  (71.6%)  
patients  in  comparison  with  the  females  (28.4%).  Anirban  Kundu  et  al  (2015)  
study  showed  18.92%  of  males  were  anti  HCV  antibody  positive  and  15.39%  
of  females  were  anti  HCV  Ab  positive48.   
Soin.D.et  al,  Paramdeep  Singh  et  al,  and  Ganesh  Kumar  Anbazhagan  
et  al  also  have  shown  male  predominance  in  their  studies,  which  indicates  
a  reasonably  higher  proportion  in  males  than  females  in  HCV  infection  could  
be  a  reflection  of  more  males  coming  for  treatment  in  our  setting57,56,16.  
Besides  it  could  be  due  to  more  social  mobility  in  males  than  females  and  
thus  greater  vulnerability  to  be  infected.  Another  factor  may  be  that  in  the  
study  group  the  males  outnumbered  the  females,  so  there  might  have  been  
overrepresentation  of  the  males. 
Abel  Girma  Ayele  et  al  (2013),  Muhammad  Usman  Anjum  et  al  
(2015),  Muhammad  Ali  Tahit  et  al  (2015)  and  Charles  E  Ramarokoto  
(2008)51,72,75,76    studies  showed  female  predominance. 
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The  present  study  showed  sero-prevalence  was  more  in  rural  area  
than  urban.  This  finding  goes  in  correlation  with  studies  done  by  Anirban  
Kundu  et  al,  A  Muhammed  Ali  Tahiret  al  (2015)  and  Anuj  Sharma  et  al  
(2014)50,76,77.  This  could  be  explained  to  be  due  to  unsafe  injection  practices  
even  now  prevailing  in  the  rural  areas  of  our  country,  the  most  common  
mode  of  transmission  of  blood  borne  infections  like  HCV.  It  needs  to  be  
mentioned  that  the  rural  population  are  still  dependent  upon  the  untrained  
paramedics  for  their  treatment  needs. 
Qu  JB  et  al  (2000),  Schinichiro  et  al  (1997)  studies  showed  no  
substantial  difference  between  urban  and  rural  population79,  80.  High  
prevalence  in  urban  population  observed  in  Shahin  Merat  et  al  (2010),  Abel  
Girma  Ayele  et  al  (2013)  81,51  may  be  due  to  migration  of  people    from  
different  geographical    areas  ,    dense  population,  change  in  life  style  and  
exposure  to  various  risk  factors  especially  like  intravenous  drug  abuse,    
multiple  blood  transfusion  and  unprotected  sexual  promiscuity  etc., 
Hepatitis  C  virus  is  transmitted  primarily  through  the  parenteral  route  and  
source  of  infection  include  transfusion  of  blood  and  its  products,  unsafe  
therapeutic  interventions,  drug  abuse,  needle  stick  injuries,  hairdressing  and  
tattooing. 
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Most  frequent  risk  factor  for  HCV  transmission  in  this  study  was  IV  drug  
abuse  observed  in  33%  of  cases  followed  by  blood  transfusion  in  24%,  
haemodialysis  in  22%,  surgery  in  21%  and  unsafe  injection  in  19%. 
The  prevalence  of  Anti-HCV  antibodies  was  33%  among  intravenous  
drug  users  in  this  study.  This  finding  is  also  supported  by  Basu  D  et  al  
(2013)66  showed  prevalence  of  31.8%  and  study  done  at  YRGCARE  Chennai  
which  reported  prevalence  of  55%.  This  could  be  explained  by  the  fact  that  
Injection  drug  users  are  at  risk  for  blood-borne  pathogen,  including  Hepatitis  
C  virus,  Hepatitis  B  virus  and  HIV.  In  developed  countries,  HCV  is  
predominantly  transmitted  by  intravenous  drug  abusers.  Drug  sharing  and  
preparation  practices  are  responsible  for  transmission  of  HCV.  Sharing  
partners  are  necessary  to  sustain  transmission  of  HCV  virus. 
Blood  transfusion  history  was  elicited  in  24%  sero-positive  cases.  This  
finding  correlates  well  with  study  by  Amarapurkar  et  al  (2001)68  which  
showed  38%  and  Abel  Girma  Ayele  et  al  (2013)49  study  with  21.5%.    Blood  
transfusion  was  responsible  for  about  sixty  one  percent  of  cases  with  chronic  
HCV  infection  according  to  a  study  from  Vellore  by  Seeff  et  al  (1992)78.  
This  could  be  attributed  to  the  fact  that  blood  transfusion  allows  a  large  
quantum  of  infective  virions  into  the  susceptible  patient.   
In  the  present  study,  22%  (5/21)  of  patients  with  chronic  renal  failure  
on  long  term  haemodialysis  were  found  to  be  positive  for  anti  HCV  antibody.  
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Similar  finding  was  observed  by  Divya  Soin  et  al  (2015)  and  Rubina  
Malhotra  et  al  (2016)57,69.  Multiple  blood  transfusions  and  haemodialysis  were  
also  significant  risk  factors  observed  in  this  study,  which  could  be  explained  
by  the  fact  that  patients  on  haemodialysis  are  at  an  increased  risk  for  
acquiring  HCV  as  a  result  of  multiple  blood  transfusions  and  cross  
contamination  from  dialysis  circuit.  Stringent  blood  screening  and  Strict  
infection  practices  in  dialysis  unit  are  required  for  reduction  of  transmission. 
  The  antibody  protection  is  poor  in  patients  on  chronic  haemodialysis  and  
after  renal  transplantation  due  to  immunosuppression.  The  ELISA  alone  may  
fail  to  detect  the  HCV  infection  in  these  cases.  HCV  RNA  testing  should  
be  made  mandatory  for  these  patients. 
Among  kidney  transplants,  the  prevalence  was  reported  to  be  as  high  
as  55.9%  by  Radhakrishnan  et  al  (2000)  and  26.2%  by  Gosavi  et  al  (1997),  
since  most  of  these  kidney  transplant  patients  underwent  dialysis  and  received  
multiple  blood  transfusion  prior  to  transplant76,77. 
Health  care  workers  have  an  increased  risk  of  acquiring  hepatitis  
infection.  One  patient  in  this  study  was  a  staff  worked  in  a  dialysis  unit  got  
infected  and  now  under  antiviral  treatment.   
In  many  developing  countries  like  India,  an  important  risk  factor  for  
HCV  is  contaminated  syringes.  In  many  places  of  India,  supplies  of  sterile  
syringes  may  not  be  available  or  non-medical  professionals  often  give  
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injection  outside  the  hospital.  In  this  scenario,  people  may  receive  multiple  
contaminated  injections  over  a  period  of  time  which  increases  the  risk  of  
HCV  infection.   
Nineteen  percent  of  cases  gave  history  of  unsafe  injection  in  this  
study.  The  reason  probably  could  be  many  patients  believe  that  injectable  
and  intravenous  fluids  act  faster  and  relieve  the  symptoms  more  quickly  than  
oral  drugs.  A  high  frequency  of  injection  use,  most  of  which  are  administered  
under  unsterile  conditions,  put  the  patients  on  risk  of  acquiring  HCV  
infection.   
Qualitative  HCV  RNA  tests  are  used  to  confirm  the  presence  of  
Hepatitis  C  virus.    RT-PCR    can  be  used  for  quantitative  measurement  of  
viraemia  for   diagnosis  in  acute  HCV  infection,  in  case  of  anti-HCV-negative  
chronic  hepatitis  C  carriers,   for  evaluation  of  HCV  viraemia  in  asymptomatic  
patients  with  normal  liver  enzymes,  for  assessing    as  well  as    predicting  
treatment  response  and  also    assessing  the  severity  of  disease.   
Among  200  cases  of  chronic  liver  disease  tested  for  HCV  -RNA,  29  (14.5%)  
were  positive.  This  is  consistent  with  the  studies  by  Anita  Chakravarti  et  al  
(2011)  26,   Mohan   KV   et   al   (1999)66.    HCV-  RNA  detection  rate  of  
24.66%  was  observed  by  D.  B.  Senevirathna  et  al  (2014),  27.95%  by                                
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B.Kazemi  et  al (  2004)70,  66.6%  by  Caldwell  SH  et  al69,  and    73.6%  by  
L.K.  Silva  et  al  (2006)68  .   
The  variation  in  the  HCV  RNA  detection  rate  among  sero-positive  
cases  could  be  due  to  intermittent  viremia  or  spontaneous  resolution  of  
infection.  Other  possibilities  are  underestimation  of  viremia  in  patients  is  due  
to  the  fact  that  virus  is  present  only  in  hepatocytes.  Out  of  56    cases  positive    
by  ELISA  ,    only  26  (46.42%)  were  confirmed  by  real  time  RT-PCR  
indicating  the  HCV  infection  is  active. 
Sero-positivity  among  PCR  negative  patients  may  be  due  to  cross  
reaction  with  non-specific  antibody.  Hence,  all  the  anti-  HCV  positive  results  
should  be  confirmed  by  testing  for  HCV  RNA. 
Alternatively,  true  antibody-positive  participants  did  not  have  positive  
RT-PCR  results  because  they  had  intermittent  viremia  or  spontaneously  
cleared  HCV  infection.   
In  the  present  study,  3  samples  from  patients  undergoing  dialysis  were  
negative  by  ELISA,  whereas  positive  by  PCR.  This  may  be  due  to  antibody  
synthesis  is  low  in  immunocompromised  state  of  patients  like  in  chronic  
kidney  disease,  when  compared  to  normal  individual. 
The  sensitivity  and  the  specificity  of  ELISA  in  this  study  were  89%  
and  72%  respectively.  Though  it  was  good  enough    as  a    diagnostic  assay,  
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all  the  ELISA  positive  cases  should  be  confirmed  by  testing  for  HCV  RNA,  
as  the  specificity  of    RT-PCR  was  absolute  at  high  sensitivity  (100%),  which  
is  not  only  suitable  for  clinical  diagnosis  and  also  recommended  for  the  
HCV   screening  in  order  to  prevent  the  transmission  of   this  disease. 
This  study  showed  mean  of  liver  enzymes  ALT,  ALP  of  60,  200.52IU 
respectively.  This  is  accordance  with  the  fact  that  liver  parameters  in  HCV  
are  fluctuating  and  sometimes  normal.  This  finding  is  comparable  to  study  
by  Usha  Arora  et  al  (2007)   predominant  sign  among  2  HCV  Ab                
positive  cases.   
It  is  reported  in  the  literature  that  patients  with  HCV  infection  may  
present  in  anicteric,  icteric  or  fulminant  form.  So  it  can’t  be  distinguished  
solely  by  clinical  features  or  by  biochemical  markers  and  therefore  serology  
is  must.   
No  case  of  co-infection  like  HBV,  HIV  with  HCV  was  reported  in  
the  present  study. 
HCV  positivity  in  HIV  was  found  to  have  abnormal  liver  parameters  
compared  to  patients  who  are  not  infected  with  HCV.   
Thiagarajan  SP  et  al  reported  HBV  and  HCV  co-  infection  has  been  
reported  in  12%  of  patients  with  chronic  liver  disease  and  11.7%  
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Hepatocellular  carcinoma  .HCV  superinfection  can  cause  a  much  more  severe  
liver  disease  in  patients  with  chronic  HBV  infection.   
Analysis  of  the  HCV  genome  has  shown  extreme  variability  in  both  
structural  and  non-structural  coding  regions.  This  analysis  has  identified  at  
least  six  different  genotypes  which  are  divided  into  several  subtypes.  HCV  
genotype  is  the  strongest  predictor  of  response  to  treatment.  Different  
genotype  will  respond  in  a  different  way  to  alpha  interferon. 
The  distribution  of  HCV  genotypes  vary  according  to  geographical  
region.  Genotypes  1,  2  and  3  are  widely  distributed  throughout  the  world,  
but  the  other  genotypes  are  common  in  particular  geographic  region.  Study  
of  HCV  genotypes  within  a  population  is  a  useful  for  the  study  of  the  
evolution  of  HCV  infection  in  different    regions. 
The  present  study  showed  genotype  3  (57.6%)  was  the  major  genotype  
which  is  similar  to  studies  by  Anita  Chakravarti  et  al  (2011),  Chistdas  et  al  
(2013).  This  is  in  contrast  to  findings  by  Chandra  et  al  (2003),  Valliammal  
et  al  (1995),  Saravanan  et  al  (2008)  in  which  genotype  1  is  prevalent.  
Genotype  1  is  observed  in  4(13.7%)  cases  in  this  study. 
The  presumption  of  an  Asian  origin  of  HCV  genotype  3  depends  on  
a  large  number  of  subtypes  of  HCV  genotype  3  that  were  isolated  in  this  
area.  This  suggests  that  genotype  has  been  present  in  Asian  population  for  
many  centuries.   
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Genotype  4  is  found  in  6(23%)  patients  in  our  study.  This  goes  similar  
to  findings  by  Raghuraman.S  et  al  (2004)  study.  Genotype  4  is  mainly  seen  
in  Egypt  and  Middle  East,  now  shows  a  rise  in  trend  in  South  India. 
Genotype  other  than  1,2,3,4  is  seen  in  2  (7.6%)  in  this  study.  Genotype  
6  is  being  increasingly  reported  in  India  and  appears  to  be  somewhat  
geographically  restricted  in  its  distribution.    Genotype  5  is  confined  to  South  
Africa  and  Central  parts  of  France  and  has  not  yet  been  reported  from  this  
region.  Genotype  2  was  not  detected  in  our  study. 
As  per  Gower  et  al.,  genotype  1  was  the  predominant  genotype  (46%)  
worldwide  followed  by  genotype  3  (22%),  genotype  2(13%)  and  genotype  4  
in  13%. 
Genotype  3  was  common  among  older  age  group  60-70  years  whereas  
genotype  4  was  common  among  20-50  years.  Therefore  we  can  infer  that  
infection  due  to  genotype  3  in  this  region  occurred  much  earlier  in  the  past  
compared  to  other  genotypes.   
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SUMMARY 
 The  study  population  comprised  of  200  patients  with  clinically  
diagnosed  chronic  liver  disease,  majority  belonging  to  the  age  group  
of  41-70  years. 
 The  present  study  showed  that  the  sero-positivity  by  ELISA  among  
clinically  diagnosed  chronic  liver  patients  was  28%  which  indicates  
present  or  past  infection.  In  the  present  study,  13%  patients  were  both  
PCR  and  ELISA  positive  indicating  active  phase  of  infection.   
 Among  sero-positive  patients  53.6%  were  PCR  negative.  ELISA  will  
remain  positive  for  varying  period  in  persons  who  have  cleared  
infection.  False  positive  ELISA  may  occur  due  to  non-specific  binding  
or  cross  reactivity  with  other  infection.  Patients  with  ELISA  positivity  
should  be  tested  for  HCV  RNA  which  is  an  indicator  of  ongoing  
infection. 
 HCV  RNA  was  found  in  5.4%  of  ELISA  negative  patients  having  
CRF  on  long  term  dialysis  due  to  poor  antibody  response  to  Hepatitis  
C  virus  infection  in  these  patients.   
 Sero-positivity  rate  was  more  in  the  age  group  of  40-70  years.  This  
may  be  due  long  asymptomatic  period  of  infection  with  symptoms  
appearing  after  a  long  latent  period. 
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 The  male  population  testing  positive  for  Anti-HCV  antibody  was  higher  
than  female  population.  This  may  be  explained  from  the  fact  that  
males  are  more  prone  to  harbour  the  risk  factors  for  this  infection  
like  drug  abuse  and  unprotected  sex.  Several  studies  have  shown  that  
there  was  increase  in  fibrosis  progression  in  the  male  gender. 
 Sero-prevalence  was  more  in  rural  area  when  compared  to  urban  
population  duo  to  lack  of  health  care  facility  and  unsafe  injection  
practices  by  quacks  prevailing  in  the  rural  area. 
 This  study  shows  that  blood  transfusion  and  surgery  were  the  major  
route  of  transmission.  Serological  screening  of  blood  donor  population  
fails  to  detect  acute  infection. 
 Drug  sharing  and  preparation  practices  are  responsible  for  transmission  
in  intra  venous  drug  abusers. 
 Liver  enzymes  were  moderately  elevated  in  the  present  study  ALT  is  
elevated  in  35.7%  of  cases;  Elevated  AST  was  seen  in  30.35%  and  
alkaline  phosphatase  33.9%  of  cases.  Serum  bilirubin  level  was  
elevated  in  33.9%  of  patients.  Liver  parameters  were  only  moderately  
elevated  or  normal  in  chronic  HCV  patients. 
 The  present  study  describes  the  frequency  of  genotypes  in  different  
age  groups  &  genders  which  may  help  in  refinement  of  HCV  
prevention  and  therapeutic  programs. 
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 Genotype  3  was  the  commonest  type  observed  in  58.6%  patients  which  
shows  good  response  to  therapy 
 The  genotype  4  was  seen  in  20.6%  patients  showing  rising  trend  and  
associated  with  poor  prognosis. 
 Genotype  1  was  seen  in  13.7%  which  respond  poorly  to  interferon  
Alpha.  Genotype  other  than  1,2,3,4  was  observed  in  2  (6.9%)  cases.   
 Genotype  3  was  a  predominant  genotype  among  both  genders  and  in  
allage  groups 
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CONCLUSION 
 Hepatitis  C  is  a  serious  threat  with  long  term  complication.  Disease  
burden  is  likely  to  increase  in  the  few  decades.  HCV  infection  is  endemic  
in  many  geographical  regions.   
 Sero-prevalence  rate  was  high  among  CLD  patients  than  general  
population.  Significant  association  of  Hepatitis  C  virus  and  chronic  liver  
disease  was  observed  in  the  present  study.  In  the  absence  of  vaccine,  primary  
prevention  of  Hepatitis  C  should  be  targeted  to  reduce  transmission  of  virus.  
High  risk  people  should  be  provided  with  education,  counselling  and  
screening. 
 Proper  preventive  measures  like  blood  screening,  proper  sterilisation  
of  instruments,  and  proper  disposal  of  biomedical  waste  must  be  stressed. 
Third  generation  ELISA  is  an  useful  cost  effective  screening  test  for  
serological  diagnosis  of  HCV.  It  has  many  advantages  like  they  are  cost  
effective  &  easy  to  use.  RT-PCR  is  recommended  in  a  addition  to  screening  
by  ELISA  to  confirm  sero-positivity  as  ELISA  may  produce  false  positive  
results  due  to  non-specific  binding  antibodies,  cross  reaction  with  circulating  
organisms  and  in  spontaneously  cleared  cases. 
 HCV  RT-PCR  is  a  highly  sensitive  and  specific  method  for  detecting  
active  infection.  Detection  of  HCV  RNA  usually  precedes  the  antibody  
83 
 
reactivity  in  serum.  It  helps  to  rule  out  false  negative  and  weakly  positive  
ELISA  with  clinical  signs  and  symptoms  of  HCV. 
  The  present  study  highlighted  that  HCV  genotype  3  is  the  predominant  
genotype  among  chronic  liver  disease  in  our  geographical  area.  It  is  expected  
that  distribution  of  other  genotype  may  be  due  migration  of  people,  changes  
in  high  risk  behaviour  and  lifestyle.  Knowledge  of  distribution  of  genotypes  
helps  in  predicting  therapeutic  response  and  the  duration  of  treatment. 
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CONSENT FORM 
 
You, Shri./ Smt./ Kum. _________________________, aged ____ years, 
S/o / D/o / W/o ___________________________, residing at 
________________ _______________________________________ are 
request to permit you to be a participant in the research study titled Study 
on Sero-prevalence and Genotypes of Hepatitis C Virus in Chronic Liver Disease 
Patients attending a Tertiary Care Hospital  conducted by Dr. Theeba V. M., 
one of the post graduate trainees in the Dept. of Microbiology, Govt. 
Coimbatore Medical College and Hospital, Coimbatore. You are eligible 
for the study as per the inclusion criteria. You can ask him any question or 
seek from him any clarifications about the study which you may have 
before agreeing to participate in the study. 
Name  : 
Place  : 
Date  : 
Signature : 
 
  
  
        
 
 
 
 
 
 
 
      
 
 
 
 
 
 
         
HCV-case details 
Name of the patient;                                           Age/sex;  IP/OP No.;                       Date: 
Address ;            Contact No: 
 
 
Present History; 
History suggestive of Jaundice: 
H/O Hematemesis /melena: 
H/O Abdominal distension/Pedal edema: 
H/O fever/anorexia/Malaise 
Relevant past history; 
H/O Blood and blood products transfusion/surgery/unsafe injections and procedures 
H/O High risk behavior: 
G/E: Anemia/Pedal edema/dyspnea/Jaundice/varicose veins 
S/E: CVS:                  RS:                    P/A : 
Laboratory Investigation:                                                         
 Hb                              ;                                                                         Scan  ; 
 
Serum Bilurubin   Total:                                                                 Total protein   : 
                                 Direct    ;                                                             Albumen: 
                                 Indirect ;                                                             Globulin: 
SGOT       ; 
SGPT        ; 
SAP           ; 
LDH          ;                                                                                           Alpha fetoprotein:                                          
Urea         ; 
Creatinine  ; 
HCV PCR: 
Genotyping:   
                                                 WORKSHEET    
                                   Chronic liver disease patients 
 
                                      10 ml of Blood collected (2 samples, 5ml each) 
                                                                  
                 Plasma sample   (K2EDTA)                        Serum sample                                                        
                                                       
 HCV RNA by real time RT-PCR                          Anti- HCV by ELISA 
                                                                    
Positive   Negative          Positive     Negative
               
Genotyping by PCR by real time RT-PCR       
           
                       
 
 
  
 
 
  
 
 
 
 







